Gabriel Hortobagyi

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Zhang Dongwei; LaFortune Tiffany A; Krishnamurthy Savitri; Esteva Francisco J; Cristofanilli Massimo; Liu Ping; Lucci Anthony; Singh Balraj; Hung Mien-Chie; Hortobagyi Gabriel N; Ueno Naoto T
Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer.
Smith Grace L; Xu Ying; Shih Ya-Chen T; Giordano Sharon H; Smith Benjamin D; Hunt Kelly K; Strom Eric A; Perkins George H; Hortobagyi Gabriel N; Buchholz Thomas A
Breast-conserving surgery in older patients with invasive breast cancer: current patterns of treatment across the United States.
Gianni Luca; Norton Larry; Wolmark Norman; Suter Thomas M; Bonadonna Gianni; Hortobagyi Gabriel N
Role of anthracyclines in the treatment of early breast cancer.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Gabriel Hortobagyi (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Zhang Dongwei; LaFortune Tiffany A; Krishnamurthy Savitri; Esteva Francisco J; Cristofanilli Massimo; Liu Ping; Lucci Anthony; Singh Balraj; Hung Mien-Chie; Hortobagyi Gabriel N; Ueno Naoto T
Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(21):6639-48.
2009: Smith Grace L; Xu Ying; Shih Ya-Chen T; Giordano Sharon H; Smith Benjamin D; Hunt Kelly K; Strom Eric A; Perkins George H; Hortobagyi Gabriel N; Buchholz Thomas A
Breast-conserving surgery in older patients with invasive breast cancer: current patterns of treatment across the United States.
Journal of the American College of Surgeons 2009;209(4):425-433.e2.
2009: Gianni Luca; Norton Larry; Wolmark Norman; Suter Thomas M; Bonadonna Gianni; Hortobagyi Gabriel N
Role of anthracyclines in the treatment of early breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4798-808.
2009: Pusztai Lajos; Jeong Jong-Hyeon; Gong Yun; Ross Jeffrey S; Kim Chungyeul; Paik Soonmyung; Rouzier Roman; Andre Fabrice; Hortobagyi Gabriel N; Wolmark Norman; Symmans W Fraser
Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(26):4287-92.
2009: Ueno Naoto T; de Souza Jonas A; Booser Daniel; Nakayama Kazutaka; Madewell John; Wendt Richard E; Hortobagyi Gabriel N; Podoloff Donald; Champlin Richard E
Pilot study of targeted skeletal radiation therapy for bone-only metastatic breast cancer.
Clinical breast cancer 2009;9(3):173-7.
2009: Jiralerspong Sao; Palla Shana L; Giordano Sharon H; Meric-Bernstam Funda; Liedtke Cornelia; Barnett Chad M; Hsu Limin; Hung Mien-Chie; Hortobagyi Gabriel N; Gonzalez-Angulo Ana M
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(20):3297-302.
2009: Esteva Francisco J; Hortobagyi Gabriel N
Topoisomerase II{alpha} amplification and anthracycline-based chemotherapy: the jury is still out.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(21):3416-7.
2009: Yamauchi Hideko; Cristofanilli Massimo; Nakamura Seigo; Hortobagyi Gabriel N; Ueno Naoto T
Molecular targets for treatment of inflammatory breast cancer.
Nature reviews. Clinical oncology 2009;6(7):387-94.
2009: De Giorgi Ugo; Valero Vicente; Rohren Eric; Dawood Shaheenah; Ueno Naoto T; Miller M Craig; Doyle Gerald V; Jackson Summer; Andreopoulou Eleni; Handy Beverly C; Reuben James M; Fritsche Herbert A; Macapinlac Homer A; Hortobagyi Gabriel N; Cristofanilli Massimo
Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(20):3303-11.
2009: Liedtke Cornelia; Hatzis Christos; Symmans William Fraser; Desmedt Christine; Haibe-Kains Benjamin; Valero Vicente; Kuerer Henry; Hortobagyi Gabriel N; Piccart-Gebhart Martine; Sotiriou Christos; Pusztai Lajos
Genomic grade index is associated with response to chemotherapy in patients with breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(19):3185-91.
2009: Costelloe Colleen M; Rohren Eric M; Madewell John E; Hamaoka Tsuyoshi; Theriault Richard L; Yu Tse-Kuan; Lewis Valerae O; Ma Jingfei; Stafford R Jason; Tari Ana M; Hortobagyi Gabriel N; Ueno Naoto T
Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis.
The lancet oncology 2009;10(6):606-14.
2009: Lu Jing; Steeg Patricia S; Price Janet E; Krishnamurthy Savitri; Mani Sendurai A; Reuben James; Cristofanilli Massimo; Dontu Gabriela; Bidaut Luc; Valero Vicente; Hortobagyi Gabriel N; Yu Dihua
Breast cancer metastasis: challenges and opportunities.
Cancer research 2009;69(12):4951-3.
2009: Smith Benjamin D; Smith Grace L; Hurria Arti; Hortobagyi Gabriel N; Buchholz Thomas A
Future of cancer incidence in the United States: burdens upon an aging, changing nation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(17):2758-65.
2009: Hennessy Bryan T; Gonzalez-Angulo Ana-Maria; Stemke-Hale Katherine; Gilcrease Michael Z; Krishnamurthy Savitri; Lee Ju-Seog; Fridlyand Jane; Sahin Aysegul; Agarwal Roshan; Joy Corwin; Liu Wenbin; Stivers David; Baggerly Keith; Carey Mark; Lluch Ana; Monteagudo Carlos; He Xiaping; Weigman Victor; Fan Cheng; Palazzo Juan; Hortobagyi Gabriel N; Nolden Laura K; Wang Nicholas J; Valero Vicente; Gray Joe W; Perou Charles M; Mills Gordon B
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.
Cancer research 2009;69(10):4116-24.
2009: Ma Jingfei; Costelloe Colleen M; Madewell John E; Hortobagyi Gabriel N; Green Marjorie C; Cao Guang; Sun Fei; Kundra Vikas
Fast dixon-based multisequence and multiplanar MRI for whole-body detection of cancer metastases.
Journal of magnetic resonance imaging : JMRI 2009;29(5):1154-62.
2009: Srokowski Tomasz P; Fang Shenying; Hortobagyi Gabriel N; Giordano Sharon H
Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(13):2170-6.
2009: Ross Jeffrey S; Slodkowska Elzbieta A; Symmans W Fraser; Pusztai Lajos; Ravdin Peter M; Hortobagyi Gabriel N
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.
The oncologist 2009;14(4):320-68.
2009: Litton Jennifer K; Westin Shannon N; Ready Kaylene; Sun Charlotte C; Peterson Susan K; Meric-Bernstam Funda; Gonzalez-Angulo Ana M; Bodurka Diane C; Lu Karen H; Hortobagyi Gabriel N; Arun Banu K
Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation.
Cancer 2009;115(8):1598-604.
2009: Gonzalez-Angulo Ana M; Stemke-Hale Katherine; Palla Shana L; Carey Mark; Agarwal Roshan; Meric-Berstam Funda; Traina Tiffany A; Hudis Clifford; Hortobagyi Gabriel N; Gerald William L; Mills Gordon B; Hennessy Bryan T
Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(7):2472-8.
2009: Dawood S; Broglio K; Esteva F J; Yang W; Kau S-W; Islam R; Albarracin C; Yu T K; Green M; Hortobagyi G N; Gonzalez-Angulo A M
Survival among women with triple receptor-negative breast cancer and brain metastases.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(4):621-7.
2009: Arun Banu; Vogel Kristen J; Lopez Adriana; Hernandez Mike; Atchley Deann; Broglio Kristine R; Amos Christopher I; Meric-Bernstam Funda; Kuerer Henry; Hortobagyi Gabriel N; Albarracin Constance T
High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers.
Cancer prevention research (Philadelphia, Pa.) 2009;2(2):122-7.
2009: Ready Kaylene J; Vogel Kristen J; Atchley Deann P; Broglio Kristine R; Solomon Kimberly K; Amos Christopher; Lu Karen H; Hortobagyi Gabriel N; Arun Banu
Accuracy of the BRCAPRO model among women with bilateral breast cancer.
Cancer 2009;115(4):725-30.
2009: Andre Fabrice; Job Bastien; Dessen Philippe; Tordai Attila; Michiels Stefan; Liedtke Cornelia; Richon Catherine; Yan Kai; Wang Bailang; Vassal Gilles; Delaloge Suzette; Hortobagyi Gabriel N; Symmans W Fraser; Lazar Vladimir; Pusztai Lajos
Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(2):441-51.
2009: Kuerer Henry M; Albarracin Constance T; Yang Wei T; Cardiff Robert D; Brewster Abenaa M; Symmans W Fraser; Hylton Nola M; Middleton Lavinia P; Krishnamurthy Savitri; Perkins George H; Babiera Gildy; Edgerton Mary E; Czerniecki Brian J; Arun Banu K; Hortobagyi Gabriel N
Ductal carcinoma in situ: state of the science and roadmap to advance the field.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(2):279-88.
2009: Dawood Shaheenah; Broglio Kristine; Kau Shu-Wan; Green Marjorie C; Giordano Sharon H; Meric-Bernstam Funda; Buchholz Thomas A; Albarracin Constance; Yang Wei T; Hennessy Bryan T J; Hortobagyi Gabriel N; Gonzalez-Angulo Ana Maria
Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(2):220-6.
2009: Eralp Yesim; Smith Terry L; Altundag Kadri; Kau Shu-Wan; Litton Jennifer; Valero Vicente; Buzdar Aman; Hortobagyi Gabriel N; Arun Banu
Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger.
Journal of cancer research and clinical oncology 2009;135(1):141-8.
2009: Morrow Phuong Khanh H; Hortobagyi Gabriel N
Management of breast cancer in the genome era.
Annual review of medicine 2009;60():153-65.
2009: Nakayama Satoshi; Torikoshi Yasuhiro; Takahashi Takeshi; Yoshida Tomokazu; Sudo Tamotsu; Matsushima Tomoko; Kawasaki Yuko; Katayama Aya; Gohda Keigo; Hortobagyi Gabriel N; Noguchi Shinzaburo; Sakai Toshiyuki; Ishihara Hideki; Ueno Naoto T
Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells.
Breast cancer research : BCR 2009;11(1):R12.
2008: Moulder Stacy L; Symmans W Fraser; Booser Daniel J; Madden Timothy L; Lipsanen Cindy; Yuan Linda; Brewster Abenaa M; Cristofanilli Massimo; Hunt Kelly K; Buchholz Thomas A; Zwiebel James; Valero Vicente; Hortobagyi Gabriel N; Esteva Francisco J
Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(23):7909-16.
2008: Peintinger F; Buzdar A U; Kuerer H M; Mejia J A; Hatzis C; Gonzalez-Angulo A M; Pusztai L; Esteva F J; Dawood S S; Green M C; Hortobagyi G N; Symmans W F
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(12):2020-5.
2008: Dawood Shaheenah; Broglio Kristine; Valero Vicente; Reuben James; Handy Beverly; Islam Rabiul; Jackson Summer; Hortobagyi Gabriel N; Fritsche Herbert; Cristofanilli Massimo
Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?
Cancer 2008;113(9):2422-30.
2008: El Saghir Nagi S; Eniu Alexandru; Carlson Robert W; Aziz Zeba; Vorobiof Daniel; Hortobagyi Gabriel N;
Locally advanced breast cancer: treatment guideline implementation with particular attention to low- and middle-income countries.
Cancer 2008;113(8 Suppl):2315-24.
2008: Dawood Shaheenah; Broglio Kristine; Gonzalez-Angulo Ana M; Buzdar Aman U; Hortobagyi Gabriel N; Giordano Sharon H
Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(30):4891-8.
2008: Pusztai Lajos; Broglio Kristine; Andre Fabrice; Symmans W Fraser; Hess Kenneth R; Hortobagyi Gabriel N
Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(28):4679-83.
2008: Cristofanilli M; Morandi P; Krishnamurthy S; Reuben J M; Lee B-N; Francis D; Booser D J; Green M C; Arun B K; Pusztai L; Lopez A; Islam R; Valero V; Hortobagyi G N
Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(10):1713-9.
2008: Bristol Ian J; Woodward Wendy A; Strom Eric A; Cristofanilli Massimo; Domain Delora; Singletary S Eva; Perkins George H; Oh Julia L; Yu Tse-Kuan; Terrefe Welela; Sahin Aysegul A; Hunt Kelly K; Hortobagyi Gabriel N; Buchholz Thomas A
Locoregional treatment outcomes after multimodality management of inflammatory breast cancer.
International journal of radiation oncology, biology, physics 2008;72(2):474-84.
2008: Atchley Deann P; Albarracin Constance T; Lopez Adriana; Valero Vicente; Amos Christopher I; Gonzalez-Angulo Ana Maria; Hortobagyi Gabriel N; Arun Banu K
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(26):4282-8.
2008: Litton Jennifer K; Gonzalez-Angulo Ana M; Warneke Carla L; Buzdar Aman U; Kau Shu-Wan; Bondy Melissa; Mahabir Somdat; Hortobagyi Gabriel N; Brewster Abenaa M
Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(25):4072-7.
2008: Wei Yongkun; Xia Weiya; Zhang Zhihong; Liu Jinsong; Wang Huamin; Adsay Nazmi V; Albarracin Constance; Yu Dihua; Abbruzzese James L; Mills Gordon B; Bast Robert C; Hortobagyi Gabriel N; Hung Mien-Chie
Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers.
Molecular carcinogenesis 2008;47(9):701-6.
2008: Jeruss Jacqueline S; Mittendorf Elizabeth A; Tucker Susan L; Gonzalez-Angulo Ana M; Buchholz Thomas A; Sahin Aysegul A; Cormier Janice N; Buzdar Aman U; Hortobagyi Gabriel N; Hunt Kelly K
Staging of breast cancer in the neoadjuvant setting.
Cancer research 2008;68(16):6477-81.
2008: Brewster Abenaa M; Hortobagyi Gabriel N; Broglio Kristine R; Kau Shu-Wan; Santa-Maria Cesar A; Arun Banu; Buzdar Aman U; Booser Daniel J; Valero Vincente; Bondy Melissa; Esteva Francisco J
Residual risk of breast cancer recurrence 5 years after adjuvant therapy.
Journal of the National Cancer Institute 2008;100(16):1179-83.
2008: Andreopoulou Eleni; Hortobagyi Gabriel N
Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(22):3660-2.
2008: Weisenberger Daniel J; Trinh Binh N; Campan Mihaela; Sharma Shikhar; Long Tiffany I; Ananthnarayan Suchitra; Liang Gangning; Esteva Francisco J; Hortobagyi Gabriel N; McCormick Frank; Jones Peter A; Laird Peter W
DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight.
Nucleic acids research 2008;36(14):4689-98.
2008: Zhang Dongwei; Pal Ashutosh; Bornmann William G; Yamasaki Fumiyuki; Esteva Francisco J; Hortobagyi Gabriel N; Bartholomeusz Chandra; Ueno Naoto T
Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells.
Molecular cancer therapeutics 2008;7(7):1846-50.
2008: Mazouni C; Arun B; André F; Ayers M; Krishnamurthy S; Wang B; Hortobagyi G N; Buzdar A U; Pusztai L
Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers.
British journal of cancer 2008;99(1):68-71.
2008: Srokowski Tomasz P; Fang Shenying; Duan Zhigang; Buchholz Thomas A; Hortobagyi Gabriel N; Goodwin James S; Giordano Sharon H
Completion of adjuvant radiation therapy among women with breast cancer.
Cancer 2008;113(1):22-9.
2008: Dawood S; Broglio K; Esteva F J; Ibrahim N K; Kau S-W; Islam R; Aldape K D; Yu T-K; Hortobagyi G N; Gonzalez-Angulo A M
Defining prognosis for women with breast cancer and CNS metastases by HER2 status.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(7):1242-8.
2008: Buchholz Thomas A; Woodward Wendy A; Duan Zhigang; Fang Shenying; Oh Julia L; Tereffe Welela; Strom Eric A; Perkins George H; Yu Tse-Kuan; Hunt Kelly K; Meric-Bernstam Funda; Hortobagyi Gabriel N; Giordano Sharon H
Radiation use and long-term survival in breast cancer patients with T1, T2 primary tumors and one to three positive axillary lymph nodes.
International journal of radiation oncology, biology, physics 2008;71(4):1022-7.
2008: Esteva Francisco J; Hortobagyi Gabriel N
Gaining ground on breast cancer.
Scientific American 2008;298(6):58-65.
2008: Hoff Ana O; Toth Béla B; Altundag Kadri; Johnson Marcella M; Warneke Carla L; Hu Mimi; Nooka Ajay; Sayegh Gilbert; Guarneri Valentina; Desrouleaux Kimberly; Cui Jeffrey; Adamus Andrea; Gagel Robert F; Hortobagyi Gabriel N
Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2008;23(6):826-36.
2008: Andre Fabrice; Broglio Kristine; Roche Henri; Martin Miguel; Mackey John R; Penault-Llorca Frederique; Hortobagyi Gabriel N; Pusztai Lajos
Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(16):2636-43.
2008: Giordano Sharon H; Kuo Yong-Fang; Duan Zhigang; Hortobagyi Gabriel N; Freeman Jean; Goodwin James S
Limits of observational data in determining outcomes from cancer therapy.
Cancer 2008;112(11):2456-66.
2008: Rao Roshni; Feng Lei; Kuerer Henry M; Singletary S Eva; Bedrosian Isabelle; Hunt Kelly K; Ross Merrick I; Hortobagyi Gabriel N; Feig Barry W; Ames Frederick C; Babiera Gildy V
Timing of surgical intervention for the intact primary in stage IV breast cancer patients.
Annals of surgical oncology 2008;15(6):1696-702.
2008: Yang Wei T; Le-Petross Huong T; Macapinlac Homer; Carkaci Selin; Gonzalez-Angulo Ana M; Dawood Shaheenah; Resetkova Erika; Hortobagyi Gabriel N; Cristofanilli Massimo
Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings.
Breast cancer research and treatment 2008;109(3):417-26.
2008: Giordano Sharon H; Fang Shenying; Duan Zhigang; Kuo Yong-Fang; Hortobagyi Gabriel N; Goodwin James S
Use of intravenous bisphosphonates in older women with breast cancer.
The oncologist 2008;13(5):494-502.
2008: Shafee Norazizah; Smith Christopher R; Wei Shuanzeng; Kim Yoon; Mills Gordon B; Hortobagyi Gabriel N; Stanbridge Eric J; Lee Eva Y-H P
Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors.
Cancer research 2008;68(9):3243-50.
2008: Badgwell Brian D; Giordano Sharon H; Duan Zhigang Z; Fang Shenying; Bedrosian Isabelle; Kuerer Henry M; Singletary S Eva; Hunt Kelly K; Hortobagyi Gabriel N; Babiera Gildy
Mammography before diagnosis among women age 80 years and older with breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(15):2482-8.
2008: Symmans W Fraser; Hortobagyi Gabriel N
Fingerprinting lymph node metastases.
Annals of surgical oncology 2008;15(5):1275-6.
2008: Dawood Shaheenah; Broglio Kristine; Gong Yun; Yang Wei-Tse; Cristofanilli Massimo; Kau Shu-Wan; Meric-Bernstam Funda; Buchholz Thomas A; Hortobagyi Gabriel N; Gonzalez-Angulo Ana M;
Prognostic significance of HER-2 status in women with inflammatory breast cancer.
Cancer 2008;112(9):1905-11.
2008: Esteva Francisco J; Hortobagyi Gabriel N
Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer?
Journal of the National Cancer Institute 2008;100(8):521-3.
2008: Gonzalez-Angulo Ana M; Hortobagyi Gabriel N
Optimal schedule of paclitaxel: weekly is better.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(10):1585-7.
2008: Rivera Edgardo; Mejia Jaime A; Arun Banu K; Adinin Rosnie B; Walters Ronald S; Brewster Abenaa; Broglio Kristine R; Yin Guosheng; Esmaeli Bita; Hortobagyi Gabriel N; Valero Vicente
Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer.
Cancer 2008;112(7):1455-61.
2008: Dawood Shaheenah; Broglio Kristine; Gonzalez-Angulo Ana M; Kau Shu-Wan; Islam Rabiul; Hortobagyi Gabriel N; Cristofanilli Massimo
Prognostic value of body mass index in locally advanced breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(6):1718-25.
2008: Liedtke Cornelia; Mazouni Chafika; Hess Kenneth R; André Fabrice; Tordai Attila; Mejia Jaime A; Symmans W Fraser; Gonzalez-Angulo Ana M; Hennessy Bryan; Green Marjorie; Cristofanilli Massimo; Hortobagyi Gabriel N; Pusztai Lajos
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1275-81.
2008: Andre Fabrice; Mazouni Chafika; Liedtke Cornelia; Kau Shu-Wan; Frye Debby; Green Marjorie; Gonzalez-Angulo Ana M; Symmans W Fraser; Hortobagyi Gabriel N; Pusztai Lajos
HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
Breast cancer research and treatment 2008;108(2):183-90.
2008: Giordano Sharon H; Hortobagyi Gabriel N
Time to remove the subspecialty blinders: breast cancer does not exist in isolation.
Journal of the National Cancer Institute 2008;100(4):230-1.
2008: Gralow Julie R; Burstein Harold J; Wood William; Hortobagyi Gabriel N; Gianni Luca; von Minckwitz Gunter; Buzdar Aman U; Smith Ian E; Symmans William F; Singh Baljit; Winer Eric P
Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(5):814-9.
2008: Yang Jer-Yen; Zong Cong S; Xia Weiya; Yamaguchi Hirohito; Ding Qingqing; Xie Xiaoming; Lang Jing-Yu; Lai Chien-Chen; Chang Chun-Ju; Huang Wei-Chien; Huang Hsin; Kuo Hsu-Ping; Lee Dung-Fang; Li Long-Yuan; Lien Huang-Chun; Cheng Xiaoyun; Chang King-Jen; Hsiao Chwan-Deng; Tsai Fuu-Jen; Tsai Chang-Hai; Sahin Aysegul A; Muller William J; Mills Gordon B; Yu Dihua; Hortobagyi Gabriel N; Hung Mien-Chie
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation.
Nature cell biology 2008;10(2):138-48.
2008: Andre F; Nahta R; Conforti R; Boulet T; Aziz M; Yuan L X H; Meslin F; Spielmann M; Tomasic G; Pusztai L; Hortobagyi G N; Michiels S; Delaloge S; Esteva F J
Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(2):315-20.
2008: Er Ozlem; Frye Debra K; Kau Shu-Wan C; Broglio Kristine; Valero Vicente; Hortobagyi Gabriel N; Arun Banu
Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy.
Cancer journal (Sudbury, Mass.) 2008;14(1):62-8.
2008: Jeruss Jacqueline S; Mittendorf Elizabeth A; Tucker Susan L; Gonzalez-Angulo Ana M; Buchholz Thomas A; Sahin Aysegul A; Cormier Janice N; Buzdar Aman U; Hortobagyi Gabriel N; Hunt Kelly K
Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(2):246-52.
2008: Tordai Attila; Wang Jing; Andre Fabrice; Liedtke Cornelia; Yan Kai; Sotiriou Christos; Hortobagyi Gabriel N; Symmans W Fraser; Pusztai Lajos
Evaluation of biological pathways involved in chemotherapy response in breast cancer.
Breast cancer research : BCR 2008;10(2):R37.
2008: Liedtke Cornelia; Cardone Luca; Tordai Attila; Yan Kai; Gomez Henry L; Figureoa Luis J Barajas; Hubbard Rebekah E; Valero Vicente; Souchon Eduardo A; Symmans W Fraser; Hortobagyi Gabriel N; Bardelli Alberto; Pusztai Lajos
PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer.
Breast cancer research : BCR 2008;10(2):R27.
2007: Beinart Garth; Gonzalez-Angulo Ana M; Broglio Kristine; Mejia Jaime; Ruggeri Anthony; Mininberg Eric; Hortobagyi Gabriel N; Valero Vicente
Clinical course of 771 patients with bilateral breast cancer: characteristics associated with overall and recurrence-free survival.
Clinical breast cancer 2007;7(11):867-74.
2007: Altundag Kadri; Bondy Melissa L; Mirza Nadeem Q; Kau Shu-Wan; Broglio Kristine; Hortobagyi Gabriel N; Rivera Edgardo
Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis.
Cancer 2007;110(12):2640-7.
2007: Morales-Vásquez Flavia; Gonzalez-Angulo Ana Maria; Broglio Kristine; Lopez-Basave Horacio N; Gallardo Dolores; Hortobagyi Gabriel N; De La Garza Jaime G
Adjuvant chemotherapy with doxorubicin and dacarbazine has no effect in recurrence-free survival of malignant phyllodes tumors of the breast.
The breast journal 2007;13(6):551-6.
2007: Hanrahan Emer O; Gonzalez-Angulo Ana M; Giordano Sharon H; Rouzier Roman; Broglio Kristine R; Hortobagyi Gabriel N; Valero Vicente
Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(31):4952-60.
2007: Vogel Kristen J; Atchley Deann P; Erlichman Julie; Broglio Kristine R; Ready Kaylene J; Valero Vicente; Amos Christopher I; Hortobagyi Gabriel N; Lu Karen H; Arun Banu
BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(29):4635-41.
2007: Lo Hui-Wen; Hsu Sheng-Chieh; Xia Weiya; Cao Xinyu; Shih Jin-Yuan; Wei Yongkun; Abbruzzese James L; Hortobagyi Gabriel N; Hung Mien-Chie
Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression.
Cancer research 2007;67(19):9066-76.
2007: Lu Chien-Hsing; Wyszomierski Shannon L; Tseng Ling-Ming; Sun Meng-Hong; Lan Keng-Hsueh; Neal Christopher L; Mills Gordon B; Hortobagyi Gabriel N; Esteva Francisco J; Yu Dihua
Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(19):5883-8.
2007: Brewster Abenaa M; Do Kim-Anh; Thompson Patricia A; Hahn Karin M; Sahin Aysegul A; Cao Yumei; Stewart Maureen M; Murray James L; Hortobagyi Gabriel N; Bondy Melissa L
Relationship between epidemiologic risk factors and breast cancer recurrence.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(28):4438-44.
2007: Symmans W Fraser; Peintinger Florentia; Hatzis Christos; Rajan Radhika; Kuerer Henry; Valero Vicente; Assad Lina; Poniecka Anna; Hennessy Bryan; Green Marjorie; Buzdar Aman U; Singletary S Eva; Hortobagyi Gabriel N; Pusztai Lajos
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(28):4414-22.
2007: Cristofanilli Massimo; Valero Vicente; Buzdar Aman U; Kau Shu-Wan; Broglio Kristine R; Gonzalez-Angulo Ana Maria; Sneige Nour; Islam Rabiul; Ueno Naoto T; Buchholz Thomas A; Singletary Sonja E; Hortobagyi Gabriel N
Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease.
Cancer 2007;110(7):1436-44.
2007: Litton Jennifer K; Eralp Yesim; Gonzalez-Angulo Ana M; Broglio Kristine; Uyei Anne; Hortobagyi Gabriel N; Arun Banu
Multifocal breast cancer in women < or =35 years old.
Cancer 2007;110(7):1445-50.
2007: Pinder Mary C; Duan Zhigang; Goodwin James S; Hortobagyi Gabriel N; Giordano Sharon H
Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(25):3808-15.
2007: Patt Debra A; Duan Zhigang; Fang Shenying; Hortobagyi Gabriel N; Giordano Sharon H
Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(25):3871-6.
2007: Dawood Shaheenah; Gonzalez-Angulo Ana M; Peintinger Florentia; Broglio Kristine; Symmans William F; Kau Shu-Wan; Islam Rabiul; Hortobagyi Gabriel N; Buzdar Aman U
Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience.
Cancer 2007;110(6):1195-200.
2007: Arun Banu; Valero Vicente; Logan Catherine; Broglio Kristine; Rivera Edgardo; Brewster Abenaa; Yin Guosheng; Green Marjorie; Kuerer Henry; Gong Yun; Browne Doris; Hortobagyi Gabriel N; Sneige Nour
Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(16):4943-8.
2007: Lee Dung-Fang; Kuo Hsu-Ping; Chen Chun-Te; Hsu Jung-Mao; Chou Chao-Kai; Wei Yongkun; Sun Hui-Lung; Li Long-Yuan; Ping Bo; Huang Wei-Chien; He Xianghuo; Hung Jen-Yu; Lai Chien-Chen; Ding Qingqing; Su Jen-Liang; Yang Jer-Yen; Sahin Aysegul A; Hortobagyi Gabriel N; Tsai Fuu-Jen; Tsai Chang-Hai; Hung Mien-Chie
IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway.
Cell 2007;130(3):440-55.
2007: Yamasaki Fumiyuki; Zhang Dongwei; Bartholomeusz Chandra; Sudo Tamotsu; Hortobagyi Gabriel N; Kurisu Kaoru; Ueno Naoto T
Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity.
Molecular cancer therapeutics 2007;6(8):2168-77.
2007: Perez Edith A; Lerzo Guillermo; Pivot Xavier; Thomas Eva; Vahdat Linda; Bosserman Linda; Viens Patrice; Cai Can; Mullaney Brian; Peck Ronald; Hortobagyi Gabriel N
Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(23):3407-14.
2007: Peintinger Florentia; Anderson Keith; Mazouni Chafika; Kuerer Henry M; Hatzis Christos; Lin Feng; Hortobagyi Gabriel N; Symmans W Fraser; Pusztai Lajos
Thirty-gene pharmacogenomic test correlates with residual cancer burden after preoperative chemotherapy for breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(14):4078-82.
2007: Mazouni Chafika; Peintinger Florentia; Wan-Kau Shu; Andre Fabrice; Gonzalez-Angulo Ana M; Symmans W Fraser; Meric-Bernstam Funda; Valero Vicente; Hortobagyi Gabriel N; Pusztai Lajos
Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(19):2650-5.
2007: Sher Taimur; Hennessy Bryan T; Valero Vicente; Broglio Krisitine; Woodward Wendy A; Trent Jonathan; Hunt Kelly K; Hortobagyi Gabriel N; Gonzalez-Angulo Ana M
Primary angiosarcomas of the breast.
Cancer 2007;110(1):173-8.
2007: McGuire Sean E; Gonzalez-Angulo Ana M; Huang Eugene H; Tucker Susan L; Kau Shu-Wan C; Yu Tse-Kuan; Strom Eric A; Oh Julia L; Woodward Wendy A; Tereffe Welela; Hunt Kelly K; Kuerer Henry M; Sahin Aysegul A; Hortobagyi Gabriel N; Buchholz Thomas A
Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy.
International journal of radiation oncology, biology, physics 2007;68(4):1004-9.
2007: Yamasaki Fumiyuki; Johansen Mary J; Zhang Dongwei; Krishnamurthy Savitri; Felix Edward; Bartholomeusz Chandra; Aguilar Richard J; Kurisu Kaoru; Mills Gordon B; Hortobagyi Gabriel N; Ueno Naoto T
Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.
Cancer research 2007;67(12):5779-88.
2007: Camacho Luis H; Kurzrock Razelle; Cheung Alex; Barber Diane F; Gupta Sanjay; Madoff David C; Wallace Michael J; Kim E Edmund; Curley Steven A; Hortobagyi Gabriel N; Mavligit Giora
Pilot study of regional, hepatic intra-arterial paclitaxel in patients with breast carcinoma metastatic to the liver.
Cancer 2007;109(11):2190-6.
2007: Cabioglu N; Gong Y; Islam R; Broglio K R; Sneige N; Sahin A; Gonzalez-Angulo A M; Morandi P; Bucana C; Hortobagyi G N; Cristofanilli M
Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(6):1021-9.
2007: Beinart Garth A; Gonzalez-Angulo Ana M; Broglio Kristine; Frye Debbie; Walters Ronald; Holmes Frankie Ann; Gunale Shivaji; Booser Daniel; Rosenthal Julian; Dhingra Kapil; Young James A; Hortobagyi G N
Phase II trial of 10-EDAM in the treatment of metastatic breast cancer.
Cancer chemotherapy and pharmacology 2007;60(1):61-7.
2007: Craft Barbara S; Hortobagyi Gabriel N; Moulder Stacy L
Adjuvant biologic therapy for breast cancer.
Cancer journal (Sudbury, Mass.) 2007;13(3):156-61.
2007: Ross Jeffrey S; Symmans W Fraser; Pusztai Lajos; Hortobagyi Gabriel N
Standardizing slide-based assays in breast cancer: hormone receptors, HER2, and sentinel lymph nodes.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(10):2831-5.
2007: Mazouni C; Kau S-W; Frye D; Andre F; Kuerer H M; Buchholz T A; Symmans W F; Anderson K; Hess K R; Gonzalez-Angulo A M; Hortobagyi G N; Buzdar A U; Pusztai L
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(5):874-80.
2007: Andre Fabrice; Hatzis Christos; Anderson Keith; Sotiriou Christos; Mazouni Chafika; Mejia Jaime; Wang Bailiang; Hortobagyi Gabriel N; Symmans W Fraser; Pusztai Lajos
Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(7):2061-7.
2007: Hortobagyi Gabriel N;
A shortage of oncologists? The American Society of Clinical Oncology workforce study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(12):1468-9.
2007: Giordano Sharon H; Hortobagyi Gabriel N
Local recurrence or cardiovascular disease: pay now or later.
Journal of the National Cancer Institute 2007;99(5):340-1.
2007: Gong Yun; Yan Kai; Lin Feng; Anderson Keith; Sotiriou Christos; Andre Fabrice; Holmes Frankie A; Valero Vicente; Booser Daniel; Pippen John E; Vukelja Svetislava; Gomez Henry; Mejia Jaime; Barajas Luis J; Hess Kenneth R; Sneige Nour; Hortobagyi Gabriel N; Pusztai Lajos; Symmans W Fraser
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study.
The lancet oncology 2007;8(3):203-11.
2007: Cristofanilli Massimo; Broglio Kristine R; Guarneri Valentina; Jackson Summer; Fritsche Herbert A; Islam Rabiul; Dawood Shaheenah; Reuben James M; Kau Shu-Wan; Lara Juanita M; Krishnamurthy Saviti; Ueno Naoto T; Hortobagyi Gabriel N; Valero Vincente
Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden.
Clinical breast cancer 2007;7(6):471-9.
2007: Huang Eugene H; Strom Eric A; Valero Vicente; Fornage Bruno; Perkins George H; Oh Julia L; Yu Tse-Kuan; Tereffe Welela; Woodward Wendy A; Hunt Kelly K; Meric-Bernstam Funda; Sahin Aysegul A; Bedrosian Isabelle; Hortobagyi Gabriel N; Buchholz Thomas A
Locoregional treatment outcomes for breast cancer patients with ipsilateral supraclavicular metastases at diagnosis.
International journal of radiation oncology, biology, physics 2007;67(2):490-6.
2007: Mazouni Chafika; Hall Angeline; Broglio Kristine; Fritsche Herbert; Andre Fabrice; Esteva Francisco J; Hortobagyi Gabriel N; Buzdar Aman U; Pusztai Lajos; Cristofanilli Massimo
Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
Cancer 2007;109(3):496-501.
2007: Buzdar Aman U; Valero Vicente; Ibrahim Nuhad K; Francis Deborah; Broglio Kristine R; Theriault Richard L; Pusztai Lajos; Green Marjorie C; Singletary Sonja E; Hunt Kelly K; Sahin Aysegul A; Esteva Francisco; Symmans William F; Ewer Michael S; Buchholz Thomas A; Hortobagyi Gabriel N
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(1):228-33.
2007: Esteva Francisco J; Wang Jing; Lin Feng; Mejia Jaime A; Yan Kai; Altundag Kadri; Valero Vicente; Buzdar Aman U; Hortobagyi Gabriel N; Symmans W Fraser; Pusztai Lajos
CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer.
Breast cancer research : BCR 2007;9(6):R87.
2007: Gonzalez-Angulo Ana Maria; Morales-Vasquez Flavia; Hortobagyi Gabriel N
Overview of resistance to systemic therapy in patients with breast cancer.
Advances in experimental medicine and biology 2007;608():1-22.
2006: Gonzalez-Angulo Ana Maria; Sahin Aysegul; Krishnamurthy Savitry; Yang Ying; Kau Shu-Wan; Hortobagyi Gabriel N; Cristofanilli Massimo
Biologic markers in axillary node-negative breast cancer: differential expression in invasive ductal carcinoma versus invasive lobular carcinoma.
Clinical breast cancer 2006;7(5):396-400.
2006: Woodward Wendy A; Huang Eugene H; McNeese Marsha D; Perkins George H; Tucker Susan L; Strom Eric A; Middleton Lavinia; Hahn Karin; Hortobagyi Gabriel N; Buchholz Thomas A
African-American race is associated with a poorer overall survival rate for breast cancer patients treated with mastectomy and doxorubicin-based chemotherapy.
Cancer 2006;107(11):2662-8.
2006: Andre Fabrice; Mazouni Chafika; Hortobagyi Gabriel N; Pusztai Lajos
DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: current data and issues on study design.
Biochimica et biophysica acta 2006;1766(2):197-204.
2006: Gonzalez-Angulo Ana Maria; Guarneri Valentina; Gong Yun; Cristofanilli Massimo; Morales-Vasquez Flavia; Sneige Nour; Hortobagyi Gabriel N; Esteva Francisco J
Downregulation of the cyclin-dependent kinase inhibitor p27kip1 might correlate with poor disease-free and overall survival in inflammatory breast cancer.
Clinical breast cancer 2006;7(4):326-30.
2006: Rouzier Roman; Pusztai Lajos; Garbay Jean-Remi; Delaloge Suzette; Hunt Kelly K; Hortobagyi Gabriel N; Berry Donald; Kuerer Henry M
Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer.
Cancer 2006;107(7):1459-66.
2006: Huang Eugene H; Strom Eric A; Perkins George H; Oh Julia L; Chen Allen M; Meric-Bernstam Funda; Hunt Kelly K; Sahin Aysegul A; Hortobagyi Gabriel N; Buchholz Thomas A
Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score.
International journal of radiation oncology, biology, physics 2006;66(2):352-7.
2006: Rivera Edgardo; Meyers Christina; Groves Morris; Valero Vicente; Francis Deborah; Arun Banu; Broglio Kristine; Yin Guosheng; Hortobagyi Gabriel N; Buchholz Thomas
Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma.
Cancer 2006;107(6):1348-54.
2006: Guarneri Valentina; Lenihan Daniel J; Valero Vicente; Durand Jean-Bernard; Broglio Kristine; Hess Kenneth R; Michaud Laura Boehnke; Gonzalez-Angulo Ana M; Hortobagyi Gabriel N; Esteva Francisco J
Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(25):4107-15.
2006: Hess Kenneth R; Anderson Keith; Symmans W Fraser; Valero Vicente; Ibrahim Nuhad; Mejia Jaime A; Booser Daniel; Theriault Richard L; Buzdar Aman U; Dempsey Peter J; Rouzier Roman; Sneige Nour; Ross Jeffrey S; Vidaurre Tatiana; Gómez Henry L; Hortobagyi Gabriel N; Pusztai Lajos
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(26):4236-44.
2006: Hahn Karin M E; Johnson Peter H; Gordon Nancy; Kuerer Henry; Middleton Lavinia; Ramirez Mildred; Yang Wei; Perkins George; Hortobagyi Gabriel N; Theriault Richard L
Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero.
Cancer 2006;107(6):1219-26.
2006: Cristofanilli Massimo; Krishnamurthy Savitri; Guerra Laura; Broglio Kristine; Arun Banu; Booser Daniel J; Menander Kerstin; Van Wart Hood Jill; Valero Vicente; Hortobagyi Gabriel N
A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach.
Cancer 2006;107(5):935-44.
2006: Yu Zhenming; Xia Weiya; Wang Hong-Ying; Wang Shao-Chun; Pan Yong; Kwong Ka Yin; Hortobagyi Gabriel N; Hung Mien-Chie
Antitumor activity of an Ets protein, PEA3, in breast cancer cell lines MDA-MB-361DYT2 and BT474M1.
Molecular carcinogenesis 2006;45(9):667-75.
2006: Baptista Mauricio Z; Prieto Victor G; Chon Susan; Hortobagyi Gabriel N; Esteva Francisco J
Tamoxifen-related vasculitis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(21):3504-5.
2006: Giordano Sharon H; Hortobagyi Gabriel N
Leuprolide acetate plus aromatase inhibition for male breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(21):e42-3.
2006: Buchholz Thomas A; Strom Eric A; Oswald Mary Jane; Perkins George H; Oh Julia; Domain Delora; Yu Tse-Kuan; Woodward Wendy A; Tereffe Welela; Singletary S Eva; Thomas Eva; Buzdar Aman U; Hortobagyi Gabriel N; McNeese Marsha D
Fifteen-year results of a randomized prospective trial of hyperfractionated chest wall irradiation versus once-daily chest wall irradiation after chemotherapy and mastectomy for patients with locally advanced noninflammatory breast cancer.
International journal of radiation oncology, biology, physics 2006;65(4):1155-60.
2006: Day C-P; Rau K-M; Qiu L; Liu C-W; Kuo H-P; Xie X; Lopez-Berestein G; Hortobagyi G N; Hung M-C
Mutant Bik expression mediated by the enhanced minimal topoisomerase IIalpha promoter selectively suppressed breast tumors in an animal model.
Cancer gene therapy 2006;13(7):706-19.
2006: Woodward Wendy A; Vinh-Hung Vincent; Ueno Naoto T; Cheng Yee Chung; Royce Melanie; Tai Patricia; Vlastos Georges; Wallace Anne Marie; Hortobagyi Gabriel N; Nieto Yago
Prognostic value of nodal ratios in node-positive breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(18):2910-6.
2006: Giordano Sharon H; Duan Zhigang; Kuo Yong-Fang; Hortobagyi Gabriel N; Goodwin James S
Use and outcomes of adjuvant chemotherapy in older women with breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(18):2750-6.
2006: Woodward Wendy A; Giordano Sharon H; Duan Zhigang; Hortobagyi Gabriel N; Buchholz Thomas A
Supraclavicular radiation for breast cancer does not increase the 10-year risk of stroke.
Cancer 2006;106(12):2556-62.
2006: Hanrahan Emer O; Broglio Kristine; Frye Deborah; Buzdar Aman U; Theriault Richard L; Valero Vicente; Booser Daniel J; Singletary Sonja E; Strom Eric A; Gajewski James L; Champlin Richard E; Hortobagyi Gabriel N
Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
Cancer 2006;106(11):2327-36.
2006: Babiera Gildy V; Rao Roshni; Feng Lei; Meric-Bernstam Funda; Kuerer Henry M; Singletary S Eva; Hunt Kelly K; Ross Merrick I; Gwyn Karin M; Feig Barry W; Ames Frederick C; Hortobagyi Gabriel N
Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor.
Annals of surgical oncology 2006;13(6):776-82.
2006: Esteva F J; Hortobagyi G N
Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.
Breast (Edinburgh, Scotland) 2006;15(3):301-12.
2006: Nahta Rita; Yu Dihua; Hung Mien-Chie; Hortobagyi Gabriel N; Esteva Francisco J
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
Nature clinical practice. Oncology 2006;3(5):269-80.
2006: Hanrahan Emer O; Valero Vicente; Gonzalez-Angulo Ana M; Hortobagyi Gabriel N
Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(13):2113-22.
2006: Yang C H; Gonzalez-Angulo A M; Reuben J M; Booser D J; Pusztai L; Krishnamurthy S; Esseltine D; Stec J; Broglio K R; Islam R; Hortobagyi G N; Cristofanilli M
Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(5):813-7.
2006: Kaufmann Manfred; Hortobagyi Gabriel N; Goldhirsch Aron; Scholl Suzy; Makris Andreas; Valagussa Pinuccia; Blohmer Jens-Uwe; Eiermann Wolfgang; Jackesz Raimund; Jonat Walter; Lebeau Annette; Loibl Sibylle; Miller William; Seeber Sigfried; Semiglazov Vladimir; Smith Roy; Souchon Rainer; Stearns Vered; Untch Michael; von Minckwitz Gunter
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(12):1940-9.
2006: Avis Nancy E; Smith Kevin W; Link Carol L; Hortobagyi Gabriel N; Rivera Edgardo
Factors associated with participation in breast cancer treatment clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(12):1860-7.
2006: Hennessy B T; Giordano S; Broglio K; Duan Z; Trent J; Buchholz T A; Babiera G; Hortobagyi G N; Valero V
Biphasic metaplastic sarcomatoid carcinoma of the breast.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(4):605-13.
2006: Anderson Keith; Hess Kenneth R; Kapoor Mini; Tirrell Stephen; Courtemanche Jean; Wang Bailiang; Wu Yun; Gong Yun; Hortobagyi Gabriel N; Symmans W Fraser; Pusztai Lajos
Reproducibility of gene expression signature-based predictions in replicate experiments.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(6):1721-7.
2006: Giordano Sharon H; Duan Zhigang; Kuo Yong-Fang; Hortobagyi Gabriel N; Freeman Jean; Goodwin James S
Impact of a scientific presentation on community treatment patterns for primary breast cancer.
Journal of the National Cancer Institute 2006;98(6):382-8.
2006: Guarneri Valentina; Broglio Kristine; Kau Shu-Wan; Cristofanilli Massimo; Buzdar Aman U; Valero Vicente; Buchholz Thomas; Meric Funda; Middleton Lavinia; Hortobagyi Gabriel N; Gonzalez-Angulo Ana M
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(7):1037-44.
2006: Hennessy Bryan T; Gonzalez-Angulo Ana Maria; Hortobagyi Gabriel N; Cristofanilli Massimo; Kau Shu Wan; Broglio Kristine; Fornage Bruno; Singletary S Eva; Sahin Aysegul; Buzdar Aman U; Valero Vicente
Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy.
Cancer 2006;106(5):1000-6.
2006: Ocaña Alberto; Hortobagyi Gabriel N; Esteva Francisco J
Concomitant versus sequential chemotherapy in the treatment of early-stage and metastatic breast cancer.
Clinical breast cancer 2006;6(6):495-504.
2006: Fentiman Ian S; Fourquet Alain; Hortobagyi Gabriel N
Male breast cancer.
Lancet 2006;367(9510):595-604.
2006: Chen I-Fen; Ou-Yang Fu; Hung Jen-Yu; Liu Jaw-Ching; Wang Hongying; Wang Shao-Chun; Hou Ming-Feng; Hortobagyi Gabriel N; Hung Mien-Chie
AIM2 suppresses human breast cancer cell proliferation in vitro and mammary tumor growth in a mouse model.
Molecular cancer therapeutics 2006;5(1):1-7.
2006: Ou-Yang Fu; Lan Keng-Li; Chen Chun-Te; Liu Jaw-Ching; Weng Chu-Li; Chou Chao-Kai; Xie Xiaoming; Hung Jen-Yu; Wei Yongkun; Hortobagyi Gabriel N; Hung Mien-Chie
Endostatin-cytosine deaminase fusion protein suppresses tumor growth by targeting neovascular endothelial cells.
Cancer research 2006;66(1):378-84.
2005: Ross Jeffrey S; Symmans W Fraser; Pusztai Lajos; Hortobagyi Gabriel N
Pharmacogenomics and clinical biomarkers in drug discovery and development.
American journal of clinical pathology 2005;124 Suppl():S29-41.
2005: Albain Kathy S; de la Garza Salazar Jaime; Pienkowski Tadeusz; Aapro Matti; Bergh Jonas; Caleffi Maira; Coleman Robert; Eiermann Wolfgang; Icli Fikri; Pegram Mark; Piccart Martine; Snyder Raymond; Toi Masakazu; Hortobagyi Gabriel N
Reducing the global breast cancer burden: the importance of patterns of care research.
Clinical breast cancer 2005;6(5):412-20.
2005: Hortobagyi Gabriel N; de la Garza Salazar Jaime; Pritchard Kathleen; Amadori Dino; Haidinger Renate; Hudis Clifford A; Khaled Hussein; Liu Mei-Ching; Martin Miguel; Namer Moise; O'Shaughnessy Joyce A; Shen Zhen Zhou; Albain Kathy S;
The global breast cancer burden: variations in epidemiology and survival.
Clinical breast cancer 2005;6(5):391-401.
2005: Hennessy Bryan T; Hortobagyi Gabriel N; Rouzier Roman; Kuerer Henry; Sneige Nour; Buzdar Aman U; Kau Shu Wan; Fornage Bruno; Sahin Aysegul; Broglio Kristine; Singletary S Eva; Valero Vicente
Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(36):9304-11.
2005: Hennessy Bryan T; Gonzalez-Angulo Ana Maria; Hortobagyi Gabriel N
Individualization of neoadjuvant therapy for breast cancer according to molecular tumor characteristics.
Nature clinical practice. Oncology 2005;2(12):598-9.
2005: Symmans W F; Fiterman D J; Anderson S K; Ayers M; Rouzier R; Dunmire V; Stec J; Valero V; Sneige N; Albarracin C; Wu Y; Ross J S; Wagner P; Theriault R L; Arun B; Kuerer H; Hess K R; Zhang W; Hortobagyi G N; Pusztai L
A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding.
Endocrine-related cancer 2005;12(4):1059-69.
2005: Buchholz Thomas A; Garg Amit K; Chakravarti Nitin; Aggarwal Bharat B; Esteva Francisco J; Kuerer Henry M; Singletary S Eva; Hortobagyi Gabriel N; Pusztai Lajos; Cristofanilli Massimo; Sahin Aysegul A
The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(23):8398-402.
2005: Giordano Sharon H; Perkins George H; Broglio Kristine; Garcia Sherry G; Middleton Lavinia P; Buzdar Aman U; Hortobagyi Gabriel N
Adjuvant systemic therapy for male breast carcinoma.
Cancer 2005;104(11):2359-64.
2005: Rouzier Roman; Pusztai Lajos; Delaloge Suzette; Gonzalez-Angulo Ana M; Andre Fabrice; Hess Kenneth R; Buzdar Aman U; Garbay Jean-Remi; Spielmann Marc; Mathieu Marie-Christine; Symmans W Fraser; Wagner Peter; Atallah David; Valero Vicente; Berry Donald A; Hortobagyi Gabriel N
Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(33):8331-9.
2005: Hennessy Bryan T; Krishnamurthy Savitri; Giordano Sharon; Buchholz Thomas A; Kau Shu W; Duan Zhigang; Valero Vicente; Hortobagyi Gabriel N
Squamous cell carcinoma of the breast.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(31):7827-35.
2005: Hortobagyi Gabriel N
Trastuzumab in the treatment of breast cancer.
The New England journal of medicine 2005;353(16):1734-6.
2005: Schechter Naomi R; Strom Eric A; Perkins George H; Arzu Isadora; McNeese Marsha D; Langstein Howard N; Kronowitz Steven J; Meric-Bernstam Funda; Babiera Gildy; Hunt Kelly K; Hortobagyi Gabriel N; Buchholz Thomas A
Immediate breast reconstruction can impact postmastectomy irradiation.
American journal of clinical oncology 2005;28(5):485-94.
2005: Gonzalez-Angulo Ana M; McGuire Sean E; Buchholz Thomas A; Tucker Susan L; Kuerer Henry M; Rouzier Roman; Kau Shu-Wan; Huang Eugene H; Morandi Paolo; Ocana Alberto; Cristofanilli Massimo; Valero Vicente; Buzdar Aman U; Hortobagyi Gabriel N
Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(28):7098-104.
2005: Patt Debra A; Goodwin James S; Kuo Yong-Fang; Freeman Jean L; Zhang Dong D; Buchholz Thomas A; Hortobagyi Gabriel N; Giordano Sharon H
Cardiac morbidity of adjuvant radiotherapy for breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(30):7475-82.
2005: Gianni Luca; Zambetti Milvia; Clark Kim; Baker Joffre; Cronin Maureen; Wu Jenny; Mariani Gabriella; Rodriguez Jaime; Carcangiu Marialuisa; Watson Drew; Valagussa Pinuccia; Rouzier Roman; Symmans W Fraser; Ross Jeffrey S; Hortobagyi Gabriel N; Pusztai Lajos; Shak Steven
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(29):7265-77.
2005: Ibrahim Nuhad K; Samuels Brian; Page Ray; Doval Dinesh; Patel Kirtikumar M; Rao S C; Nair Madhavan Krishnan; Bhar Paul; Desai Neil; Hortobagyi Gabriel N
Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(25):6019-26.
2005: Green Marjorie C; Buzdar Aman U; Smith Terry; Ibrahim Nuhad K; Valero Vicente; Rosales Marguerite F; Cristofanilli Massimo; Booser Daniel J; Pusztai Lajos; Rivera Edgardo; Theriault Richard L; Carter Cynthia; Frye Debra; Hunt Kelly K; Symmans W Fraser; Strom Eric A; Sahin Aysegul A; Sikov William; Hortobagyi Gabriel N
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(25):5983-92.
2005: Hanrahan Emer O; Broglio Kristine R; Buzdar Aman U; Theriault Richard L; Valero Vicente; Cristofanilli Massimo; Yin Guosheng; Kau Shu-Wan C; Hortobagyi Gabriel N; Rivera Edgardo
Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors.
Cancer 2005;104(6):1158-71.
2005: Hunt Kelly K; Buchholz Thomas A; Hortobagyi Gabriel N
Now and later? The sticky question of lymph node management in patients receiving preoperative chemotherapy.
Annals of surgical oncology 2005;12(9):683-5.
2005: Cabioglu Neslihan; Yazici M Sertac; Arun Banu; Broglio Kristine R; Hortobagyi Gabriel N; Price Janet E; Sahin Aysegul
CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(16):5686-93.
2005: Rouzier Roman; Perou Charles M; Symmans W Fraser; Ibrahim Nuhad; Cristofanilli Massimo; Anderson Keith; Hess Kenneth R; Stec James; Ayers Mark; Wagner Peter; Morandi Paolo; Fan Chang; Rabiul Islam; Ross Jeffrey S; Hortobagyi Gabriel N; Pusztai Lajos
Breast cancer molecular subtypes respond differently to preoperative chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(16):5678-85.
2005: Stec James; Wang Jing; Coombes Kevin; Ayers Mark; Hoersch Sebastian; Gold David L; Ross Jeffrey S; Hess Kenneth R; Tirrell Stephen; Linette Gerald; Hortobagyi Gabriel N; Fraser Symmans W; Pusztai Lajos
Comparison of the predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and Affymetrix GeneChips.
The Journal of molecular diagnostics : JMD 2005;7(3):357-67.
2005: Pusztai Lajos; Wagner Peter; Ibrahim Nuhad; Rivera Edgardo; Theriault Richard; Booser Daniel; Symmans Fraser W; Wong Franklin; Blumenschein George; Fleming Donald R; Rouzier Roman; Boniface Graeme; Hortobagyi Gabriel N
Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma.
Cancer 2005;104(4):682-91.
2005: Buchholz Thomas A; Tu Xiaoyu; Ang K Kian; Esteva Francisco J; Kuerer Henry M; Pusztai Lajos; Cristofanilli Massimo; Singletary S Eva; Hortobagyi Gabriel N; Sahin Aysegul A
Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy.
Cancer 2005;104(4):676-81.
2005: Hennessy B T; Gauthier A M; Michaud L B; Hortobagyi G; Valero V
Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(8):1289-96.
2005: Montero Alberto J; Rouzier Roman; Lluch Ana; Theriault Richard L; Buzdar Aman U; Delaloge Suzette; Bermejo Begoñia; Le Monique; Kau Shu-Wan; Dunant Ariane; Arriagada Rodrigo; Spielmann Marc; Garcia-Conde Javier; Sahin Aysegul A; Singletary Sonja E; Hortobagyi Gabriel N; Valero Vicente
The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study.
Cancer 2005;104(2):229-35.
2005: Rouzier Roman; Rajan Radhika; Wagner Peter; Hess Kenneth R; Gold David L; Stec James; Ayers Mark; Ross Jeffrey S; Zhang Peter; Buchholz Thomas A; Kuerer Henry; Green Marjorie; Arun Banu; Hortobagyi Gabriel N; Symmans W Fraser; Pusztai Lajos
Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(23):8315-20.
2005: Huang Eugene H; Tucker Susan L; Strom Eric A; McNeese Marsha D; Kuerer Henry M; Hortobagyi Gabriel N; Buzdar Aman U; Valero Vicente; Perkins George H; Schechter Naomi R; Hunt Kelly K; Sahin Aysegul A; Buchholz Thomas A
Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy.
International journal of radiation oncology, biology, physics 2005;62(2):351-7.
2005: Gonzalez-Angulo Ana M; Broglio Kristine; Kau Shu-Wan; Eralp Yesmin; Erlichman Julie; Valero Vicente; Theriault Richard; Booser Daniel; Buzdar Aman U; Hortobagyi Gabriel N; Arun Banu
Women age < or = 35 years with primary breast carcinoma: disease features at presentation.
Cancer 2005;103(12):2466-72.
2005: Buzdar Aman U; Ibrahim Nuhad K; Francis Deborah; Booser Daniel J; Thomas Eva S; Theriault Richard L; Pusztai Lajos; Green Marjorie C; Arun Banu K; Giordano Sharon H; Cristofanilli Massimo; Frye Debra K; Smith Terry L; Hunt Kelly K; Singletary Sonja E; Sahin Aysegul A; Ewer Michael S; Buchholz Thomas A; Berry Donald; Hortobagyi Gabriel N
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(16):3676-85.
2005: Esteva Francisco J; Sahin Aysegul A; Cristofanilli Massimo; Coombes Kevin; Lee Sang-Joon; Baker Joffre; Cronin Maureen; Walker Michael; Watson Drew; Shak Steven; Hortobagyi Gabriel N
Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(9):3315-9.
2005: Hortobagyi Gabriel N
Progress in the management of bone metastases: one continent at a time?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(15):3299-301.
2005: Giordano Sharon H; Kuo Yong-Fang; Freeman Jean L; Buchholz Thomas A; Hortobagyi Gabriel N; Goodwin James S
Risk of cardiac death after adjuvant radiotherapy for breast cancer.
Journal of the National Cancer Institute 2005;97(6):419-24.
2005: Cristofanilli Massimo; Hayes Daniel F; Budd G Thomas; Ellis Mathew J; Stopeck Alison; Reuben James M; Doyle Gerald V; Matera Jeri; Allard W Jeffrey; Miller M Craig; Fritsche Herbert A; Hortobagyi Gabriel N; Terstappen Leon W M M
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(7):1420-30.
2005: Cristofanilli Massimo; Yamamura Yuko; Kau Shu-Wan; Bevers Therese; Strom Sara; Patangan Modesto; Hsu Limin; Krishnamurthy Savitri; Theriault Richard L; Hortobagyi Gabriel N
Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma.
Cancer 2005;103(6):1122-8.
2005: Giordano Sharon H; Hortobagyi Gabriel N; Kau Shu-Wan C; Theriault Richard L; Bondy Melissa L
Breast cancer treatment guidelines in older women.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(4):783-91.
2005: Chen Allen M; Meric-Bernstam Funda; Hunt Kelly K; Thames Howard D; Outlaw Elesyia D; Strom Eric A; McNeese Marsha D; Kuerer Henry M; Ross Merrick I; Singletary S Eva; Ames Fredrick C; Feig Barry W; Sahin Aysegul A; Perkins George H; Babiera Gildy; Hortobagyi Gabriel N; Buchholz Thomas A
Breast conservation after neoadjuvant chemotherapy.
Cancer 2005;103(4):689-95.
2005: Cristofanilli Massimo; Gonzalez-Angulo Ana; Sneige Nour; Kau Shu-Wan; Broglio Kristine; Theriault Richard L; Valero Vicente; Buzdar Aman U; Kuerer Henry; Buccholz Thomas A; Hortobagyi Gabriel N
Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(1):41-8.
2005: Ross Jeffrey S; Symmans W Fraser; Pusztai Lajos; Hortobagyi Gabriel N
Breast cancer biomarkers.
Advances in clinical chemistry 2005;40():99-125.
2005: Hortobagyi Gabriel N
Moving into the future: treatment of bone metastases and beyond.
Cancer treatment reviews 2005;31 Suppl 3():9-18.
2005: Pusztai Lajos; Symmans Fraser W; Hortobagyi Gabriel N
Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer.
Breast cancer (Tokyo, Japan) 2005;12(2):73-85.
2004: Bast Robert C; Hortobagyi Gabriel N
Individualized care for patients with cancer - a work in progress.
The New England journal of medicine 2004;351(27):2865-7.
2004: Huang Eugene H; Tucker Susan L; Strom Eric A; McNeese Marsha D; Kuerer Henry M; Buzdar Aman U; Valero Vicente; Perkins George H; Schechter Naomi R; Hunt Kelly K; Sahin Aysegul A; Hortobagyi Gabriel N; Buchholz Thomas A
Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(23):4691-9.
2004: Yu Tse-Kuan; Whitman Gary J; Thames Howard D; Buzdar Aman U; Strom Eric A; Perkins George H; Schechter Naomi R; McNeese Marsha D; Kau Shu-Wan; Thomas Eva S; Hortobagyi Gabriel N; Buchholz Thomas A
Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients.
Journal of the National Cancer Institute 2004;96(22):1676-81.
2004: Li Yan M; Pan Yong; Wei Yongkun; Cheng Xiaoyun; Zhou Binhua P; Tan Ming; Zhou Xiaoyan; Xia Weiya; Hortobagyi Gabriel N; Yu Dihua; Hung Mien-Chie
Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis.
Cancer cell 2004;6(5):459-69.
2004: Cheng Yee Chung; Rondón Gabriela; Yang Ying; Smith Terry L; Gajewski James L; Donato Michele L; Shpall Elizabeth J; Jones Roy; Hortobagyi Gabriel N; Champlin Richard E; Ueno Naoto T
The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2004;10(11):794-804.
2004: Wang B; Rouzier R; Albarracin C T; Sahin A; Wagner P; Yang Y; Smith T L; Meric-Bernstam F; Marcelo Aldaz C; Hortobagyi G N; Pusztai L
Expression of sigma 1 receptor in human breast cancer.
Breast cancer research and treatment 2004;87(3):205-14.
2004: Ross Jeffrey S; Schenkein David P; Pietrusko Robert; Rolfe Mark; Linette Gerald P; Stec James; Stagliano Nancy E; Ginsburg Geoffrey S; Symmans W Fraser; Pusztai Lajos; Hortobagyi Gabriel N
Targeted therapies for cancer 2004.
American journal of clinical pathology 2004;122(4):598-609.
2004: Gonzalez-Angulo Ana M; Cristofanilli Massimo; Strom Eric A; Buzdar Aman U; Kau Shu-Wan; Broglio Kristine R; Smith Terry L; Hortobagyi Gabriel N
Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment.
Cancer 2004;101(8):1760-6.
2004: Li Zhiyong; Ibrahim Nuhad K; Wathen Jay K; Wang Michael; Mante Menchu Rosario P; Valero Vicente; Theriault Richard; Buzdar Aman U; Hortobagyi Gabriel N
Colitis in patients with breast carcinoma treated with taxane-based chemotherapy.
Cancer 2004;101(7):1508-13.
2004: Gonzalez-Angulo Ana M; Sneige Nour; Buzdar Aman U; Valero Vicente; Kau Shu-Wan; Broglio Kristine; Yamamura Yuko; Hortobagyi Gabriel N; Cristofanilli Massimo
p53 expression as a prognostic marker in inflammatory breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(18 Pt 1):6215-21.
2004: Rouzier Roman; Hortobagyi Gabriel N
The removal of regional nodes even when "pathologically negative" for long-term survival should be discussed cautiously.
Annals of surgical oncology 2004;11(9):879-80.
2004: Resetkova Erika; Gonzalez-Angulo Ana M; Sneige Nour; Mcdonnell Timothy J; Buzdar Aman U; Kau Shu Wan; Yamamura Yuko; Reuben James M; Hortobagyi Gabriel N; Cristofanilli Massimo
Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma.
Cancer 2004;101(5):913-7.
2004: Nagata Yoichi; Lan Keng-Hsueh; Zhou Xiaoyan; Tan Ming; Esteva Francisco J; Sahin Aysegul A; Klos Kristine S; Li Ping; Monia Brett P; Nguyen Nina T; Hortobagyi Gabriel N; Hung Mien-Chie; Yu Dihua
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.
Cancer cell 2004;6(2):117-27.
2004: Buchholz Thomas A; Huang Eugene H; Berry Donald; Pusztai Lajos; Strom Eric A; McNeese Marsha D; Perkins George H; Schechter Naomi R; Kuerer Henry M; Buzdar Aman U; Valero Vicente; Hunt Kelly K; Hortobagyi Gabriel N; Sahin Aysegul A
Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy.
International journal of radiation oncology, biology, physics 2004;59(5):1337-42.
2004: Schwartz Gordon F; Hortobagyi Gabriel N; Masood Shahla; Palazzo Juan; Holland Roland; Page David;
Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, PA.
Human pathology 2004;35(7):781-4.
2004: Hamaoka Tsuyoshi; Madewell John E; Podoloff Donald A; Hortobagyi Gabriel N; Ueno Naoto T
Bone imaging in metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(14):2942-53.
2004: Gonzalez-Angulo Ana M; Krishnamurthy Savitri; Yamamura Yuko; Broglio Kristine R; Pusztai Lajos; Buzdar Aman U; Hortobagyi Gabriel N; Esteva Francisco J
Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma.
Cancer 2004;101(2):258-63.
2004: Giordano Sharon H; Cohen Deborah S; Buzdar Aman U; Perkins George; Hortobagyi Gabriel N
Breast carcinoma in men: a population-based study.
Cancer 2004;101(1):51-7.
2004: Ross Jeffrey S; Schenkein David P; Kashala Oscar; Linette Gerald P; Stec James; Symmans W Fraser; Pusztai Lajos; Hortobagyi Gabriel N
Pharmacogenomics.
Advances in anatomic pathology 2004;11(4):211-20.
2004: Schwartz Gordon F; Hortobagyi Gabriel N
Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania.
Cancer 2004;100(12):2512-32.
2004: Chen Allen M; Meric-Bernstam Funda; Hunt Kelly K; Thames Howard D; Oswald Mary Jane; Outlaw Elesyia D; Strom Eric A; McNeese Marsha D; Kuerer Henry M; Ross Merrick I; Singletary S Eva; Ames Fredrick C; Feig Barry W; Sahin Aysegul A; Perkins George H; Schechter Naomi R; Hortobagyi Gabriel N; Buchholz Thomas A
Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(12):2303-12.
2004: Thomas Eva; Holmes Frankie A; Smith Terry L; Buzdar Aman U; Frye Debra K; Fraschini Giuseppe; Singletary S Eva; Theriault Richard L; McNeese Marsha D; Ames Frederick; Walters Ronald; Hortobagyi Gabriel N
The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(12):2294-302.
2004: Ayers M; Symmans W F; Stec J; Damokosh A I; Clark E; Hess K; Lecocke M; Metivier J; Booser D; Ibrahim N; Valero V; Royce M; Arun B; Whitman G; Ross J; Sneige N; Hortobagyi G N; Pusztai L
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(12):2284-93.
2004: Hortobagyi Gabriel N
What is the role of high-dose chemotherapy in the era of targeted therapies?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(12):2263-6.
2004: Pusztai Lajos; Gregory Betsy W; Baggerly Keith A; Peng Bo; Koomen John; Kuerer Henry M; Esteva Francisco J; Symmans W Fraser; Wagner Peter; Hortobagyi Gabriel N; Laronga Christine; Semmes O John; Wright George L; Drake Richard R; Vlahou Antonia
Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma.
Cancer 2004;100(9):1814-22.
2004: Garg Amit K; Strom Eric A; McNeese Marsha D; Buzdar Aman U; Hortobagyi Gabriel N; Kuerer Henry M; Perkins George H; Singletary S Eva; Hunt Kelly K; Sahin Asyegul; Schechter Naomi; Valero Vicente; Tucker Susan L; Buchholz Thomas A
T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy.
International journal of radiation oncology, biology, physics 2004;59(1):138-45.
2004: Rajan Radhika; Poniecka Anna; Smith Terry L; Yang Ying; Frye Deborah; Pusztai Lajos; Fiterman Derek J; Gal-Gombos Eva; Whitman Gary; Rouzier Roman; Green Marjorie; Kuerer Henry; Buzdar Aman U; Hortobagyi Gabriel N; Symmans W Fraser
Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.
Cancer 2004;100(7):1365-73.
2004: Ross Jeffrey S; Fletcher Jonathan A; Bloom Kenneth J; Linette Gerald P; Stec James; Symmans W Fraser; Pusztai Lajos; Hortobagyi Gabriel N
Targeted therapy in breast cancer: the HER-2/neu gene and protein.
Molecular & cellular proteomics : MCP 2004;3(4):379-98.
2004: Rivera Edgardo; Valero Vicente; Francis Deborah; Asnis Aviva G; Schaaf Larry J; Duncan Barbara; Hortobagyi Gabriel N
Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(6):1943-8.
2004: Ross Jeffrey S; Linette Gerald P; Stec James; Clark Edwin; Ayers Mark; Leschly Nick; Symmans W Fraser; Hortobagyi Gabriel N; Pusztai Lajos
Breast cancer biomarkers and molecular medicine: part II.
Expert review of molecular diagnostics 2004;4(2):169-88.
2004: Yan Duen-Hwa; Wen Yong; Su Li-Kuo; Xia Weiya; Wang Shao-Chun; Zhang Su; Gan Lin; Lee Dung-Fang; Spohn Bill; Frey Jennifer A; Hortobagyi Gabriel N; Hung Mien-Chie
A delayed chemically induced tumorigenesis in Brca2 mutant mice.
Oncogene 2004;23(10):1896-901.
2004: Kohn Elise C; Lu Yiling; Wang Hongwei; Yu Qinghua; Yu Shuangxing; Hall Hassan; Smith Debra L; Meric-Bernstam Funda; Hortobagyi Gabriel N; Mills Gordon B
Molecular therapeutics: promise and challenges.
Seminars in oncology 2004;31(1 Suppl 3):39-53.
2004: Hortobagyi Gabriel N
Opportunities and challenges in the development of targeted therapies.
Seminars in oncology 2004;31(1 Suppl 3):21-7.
2004: Cristofanilli Massimo; Gonzalez-Angulo Ana Maria; Buzdar Aman U; Kau Shu-Wan; Frye Debbie K; Hortobagyi Gabriel N
Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience.
Clinical breast cancer 2004;4(6):415-9.
2004: Navo Marisa A; Phan Julie; Vaughan Christy; Palmer J Lynn; Michaud Laura; Jones Kellie L; Bodurka Diane C; Basen-Engquist Karen; Hortobagyi Gabriel N; Kavanagh John J; Smith Judith A
An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(4):671-7.
2004: Esteva Francisco J; Sahin Aysegul A; Smith Terry L; Yang Ying; Pusztai Lajos; Nahta Rita; Buchholz Thomas A; Buzdar Aman U; Hortobagyi Gabriel N; Bacus Sarah S
Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.
Cancer 2004;100(3):499-506.
2004: Blakely L Johnetta; Buzdar Aman U; Lozada Jose A; Shullaih Samer A; Hoy Emma; Smith Terry L; Hortobagyi Gabriel N
Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence.
Cancer 2004;100(3):465-9.
2004: Pusztai Lajos; Mendoza Tito R; Reuben James M; Martinez Monica M; Willey Jie S; Lara Juanita; Syed Abdul; Fritsche Herbert A; Bruera Eduardo; Booser Daniel; Valero Vicente; Arun Banu; Ibrahim Nuhad; Rivera Edgardo; Royce Melanie; Cleeland Charles S; Hortobagyi Gabriel N
Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy.
Cytokine 2004;25(3):94-102.
2004: Cristofanilli Massimo; Singletary Eva S; Hortobagyi Gabriel N
Inflammatory breast carcinoma: the sphinx of breast cancer research.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(2):381-3; author reply 383.
2004: Giordano Sharon H; Buzdar Aman U; Smith Terry L; Kau Shu-Wan; Yang Ying; Hortobagyi Gabriel N
Is breast cancer survival improving?
Cancer 2004;100(1):44-52.
2004: Green Marjorie C; Esteva Francisco J; Hortobagyi Gabriel N
Neoadjuvant chemotherapy.
Breast disease 2004;21():23-31.
2004: Pusztai Lajos; Krishnamurti Savitri; Perez Cardona Jorge; Sneige Nour; Esteva Francisco J; Volchenok Marina; Breitenfelder Patricia; Kau Shu-Wan; Takayama Shin; Krajewski Stanislaw; Reed John C; Bast Robert C; Hortobagyi Gabriel N
Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer.
Cancer investigation 2004;22(2):248-56.
2004: Esteva Francisco J; Hortobagyi Gabriel N
Prognostic molecular markers in early breast cancer.
Breast cancer research : BCR 2004;6(3):109-18.
2003: Ross Jeffrey S; Fletcher Jonathan A; Bloom Kenneth J; Linette Gerald P; Stec James; Clark Edward; Ayers Mark; Symmans W Fraser; Pusztai Lajos; Hortobagyi Gabriel N
HER-2/neu testing in breast cancer.
American journal of clinical pathology 2003;120 Suppl():S53-71.
2003: Garg Amit K; Hortobagyi Gabriel N; Aggarwal Bharat B; Sahin Aysegul A; Buchholz Thomas A
Nuclear factor-kappa B as a predictor of treatment response in breast cancer.
Current opinion in oncology 2003;15(6):405-11.
2003: Ueno Naoto T; Cheng Yee Chung; Rondón Gabriela; Tannir Nizar M; Gajewski James L; Couriel Daniel R; Hosing Chitra; de Lima Marcos J; Anderlini Paolo; Khouri Issa F; Booser Daniel J; Hortobagyi Gabriel N; Pagliaro Lance C; Jonasch Eric; Giralt Sergio A; Champlin Richard E
Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors.
Blood 2003;102(10):3829-36.
2003: Hortobagyi Gabriel N
Novel approaches to the management of bone metastases.
Seminars in oncology 2003;30(5 Suppl 16):161-6.
2003: Buzdar Aman U; Hortobagyi Gabriel N
Sequential paclitaxel reduces recurrence and mortality in women with early breast cancer.
Cancer treatment reviews 2003;29(5):449-52.
2003: Woodward Wendy A; Strom Eric A; Tucker Susan L; Katz Angela; McNeese Marsha D; Perkins George H; Buzdar Aman U; Hortobagyi Gabriel N; Hunt Kelly K; Sahin Aysegul; Meric Funda; Sneige Nour; Buchholz Thomas A
Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation.
International journal of radiation oncology, biology, physics 2003;57(2):336-44.
2003: Woodward Wendy A; Strom Eric A; McNeese Marsha D; Perkins George H; Outlaw Eleysia L; Hortobagyi Gabriel N; Buzdar Aman U; Buchholz Thomas A
Cardiovascular death and second non-breast cancer malignancy after postmastectomy radiation and doxorubicin-based chemotherapy.
International journal of radiation oncology, biology, physics 2003;57(2):327-35.
2003: Ross Jeffrey S; Linette Gerald P; Stec James; Clark Edwin; Ayers Mark; Leschly Nick; Symmans W Fraser; Hortobagyi Gabriel N; Pusztai Lajos
Breast cancer biomarkers and molecular medicine.
Expert review of molecular diagnostics 2003;3(5):573-85.
2003: Buchholz Thomas A; Hunt Kelly K; Whitman Gary J; Sahin Aysegul A; Hortobagyi Gabriel N
Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks.
Cancer 2003;98(6):1150-60.
2003: Pusztai Lajos; Zhen Jim Hou; Arun Banu; Rivera Edgardo; Whitehead Clark; Thompson W Joseph; Nealy Kimberly M; Gibbs Amy; Symmans W Fraser; Esteva Francisco J; Booser Daniel; Murray James L; Valero Vicente; Smith Terry L; Hortobagyi Gabriel N
Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(18):3454-61.
2003: Rivera Edgardo; Valero Vicente; Arun Banu; Royce Melanie; Adinin Rosni; Hoelzer Karen; Walters Ronald; Wade James L; Pusztai Lajos; Hortobagyi Gabriel N
Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(17):3249-54.
2003: Woodward Wendy A; Strom Eric A; Tucker Susan L; McNeese Marsha D; Perkins George H; Schechter Naomi R; Singletary S Eva; Theriault Richard L; Hortobagyi Gabriel N; Hunt Kelly K; Buchholz Thomas A
Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(17):3244-8.
2003: Esteva Francisco J; Rivera Edgardo; Cristofanilli Massimo; Valero Vicente; Royce Melanie; Duggal Anil; Colucci Philippe; DeJager Robert; Hortobagyi Gabriel N
A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma.
Cancer 2003;98(5):900-7.
2003: Rivera Edgardo; Erder M Haim; Moore Timothy D; Shiftan Thomas L; Knight Chris A; Fridman Moshe; Brannan Carol; Danel-Moore Laurence; Hortobagyi Gabriel N;
Targeted filgrastim support in patients with early-stage breast carcinoma: toward the implementation of a risk model.
Cancer 2003;98(2):222-8.
2003: Trent Jonathan C; Valero Vicente; Booser Daniel J; Esparza-Guerra Laura T; Ibrahim Nuhad; Rahman Zia; Vernillet Laurent; Patel Shreyaskumar; David Cynthia L; Murray James L; Cristofanilli Massimo; Hortobagyi Gabriel N
A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(7):2426-34.
2003: Pusztai Lajos; Ayers Mark; Stec James; Clark Edward; Hess Kenneth; Stivers David; Damokosh Andrew; Sneige Nour; Buchholz Thomas A; Esteva Francisco J; Arun Banu; Cristofanilli Massimo; Booser Daniel; Rosales Marguerite; Valero Vicente; Adams Constantine; Hortobagyi Gabriel N; Symmans W Fraser
Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(7):2406-15.
2003: Chagpar Anees; Meric-Bernstam Funda; Hunt Kelly K; Ross Merrick I; Cristofanilli Massimo; Singletary S Eva; Buchholz Thomas A; Ames Frederick C; Marcy Sylvie; Babiera Gildy V; Feig Barry W; Hortobagyi Gabriel N; Kuerer Henry M
Chest wall recurrence after mastectomy does not always portend a dismal outcome.
Annals of surgical oncology 2003;10(6):628-34.
2003: Hortobagyi Gabriel N; Sauter Guido
Challenges and opportunities for Erlotinib (Tarceva): what does the future hold?
Seminars in oncology 2003;30(3 Suppl 7):47-53.
2003: Symmans W Fraser; Ayers Mark; Clark Edwin A; Stec James; Hess Kenneth R; Sneige Nour; Buchholz Thomas A; Krishnamurthy Savitri; Ibrahim Nuhad K; Buzdar Aman U; Theriault Richard L; Rosales Marguerite F M; Thomas Eva S; Gwyn Karin M; Green Marjorie C; Syed Abdul R; Hortobagyi Gabriel N; Pusztai Lajos
Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma.
Cancer 2003;97(12):2960-71.
2003: Nahta Rita; Hortobagyi Gabriel N; Esteva Francisco J
Novel pharmacological approaches in the treatment of breast cancer.
Expert opinion on investigational drugs 2003;12(6):909-21.
2003: Nahta Rita; Hortobagyi Gabriel N; Esteva Francisco J
Signal transduction inhibitors in the treatment of breast cancer.
Current medicinal chemistry. Anti-cancer agents 2003;3(3):201-16.
2003: Zhang Fan; Yang Ying; Smith Terry; Kau Shu-Wan; McConathy Judy M; Esteva Francisco J; Kuerer Henry M; Symmans W Fraser; Buzdar Aman U; Hortobagyi Gabriel N; Pusztai Lajos
Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma.
Cancer 2003;97(7):1758-65.
2003: Thomas E; Hortobagyi G N
New paradigms in adjuvant systemic therapy of breast cancer.
Endocrine-related cancer 2003;10(1):75-89.
2003: Esteva Francisco J; Glaspy John; Baidas Said; Laufman Leslie; Hutchins Laura; Dickler Maura; Tripathy Debu; Cohen Roger; DeMichele Angela; Yocum Richard C; Osborne C Kent; Hayes Daniel F; Hortobagyi Gabriel N; Winer Eric; Demetri George D
Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):999-1006.
2003: Valero Vicente; Hortobagyi Gabriel N
Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):959-62.
2003: Hess Kenneth R; Pusztai Lajos; Buzdar Aman U; Hortobagyi Gabriel N
Estrogen receptors and distinct patterns of breast cancer relapse.
Breast cancer research and treatment 2003;78(1):105-18.
2003: Buchholz Thomas A; Davis Darren W; McConkey David J; Symmans W Fraser; Valero Vicente; Jhingran Anuja; Tucker Susan L; Pusztai Lajos; Cristofanilli Massimo; Esteva Francisco J; Hortobagyi Gabriel N; Sahin Aysegul A
Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy.
Cancer journal (Sudbury, Mass.) 2003;9(1):33-41.
2003: Giordano Sharon H; Hortobagyi Gabriel N
Inflammatory breast cancer: clinical progress and the main problems that must be addressed.
Breast cancer research : BCR 2003;5(6):284-8.
2003: Hortobagyi Gabriel N
Future directions in the endocrine therapy of breast cancer.
Breast cancer research and treatment 2003;80 Suppl 1():S37-9.
2003: Hortobagyi Gabriel N
New approaches to breast cancer therapy.
Breast cancer research and treatment 2003;80 Suppl 1():S1-2; discussion S13-8.
2003: Rivera Edgardo; Haim Erder M; Fridman Moshe; Frye Debra; Hortobagyi Gabriel N
First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study.
Breast cancer research : BCR 2003;5(5):R114-20.
2002: Cristofanilli M; Hortobagyi G N
Molecular targets in breast cancer: current status and future directions.
Endocrine-related cancer 2002;9(4):249-66.
2002: Buchholz Thomas A; Stivers David N; Stec James; Ayers Mark; Clark Edward; Bolt Andrew; Sahin Aysegul A; Symmans W Fraser; Hess Kenneth R; Kuerer Henry M; Valero Vicente; Hortobagyi Gabriel N; Pusztai Lajos
Global gene expression changes during neoadjuvant chemotherapy for human breast cancer.
Cancer journal (Sudbury, Mass.) 2002;8(6):461-8.
2002: Silva Elvio G; Mistry Dinu; Li Donghui; Kuerer Henry M; Atkinson Edward N; Lopez Abel N; Shannon Rhonda; Hortobagyi Gabriel N
Elevated luteinizing hormone in serum, breast cancer tissue, and normal breast tissue from breast cancer patients.
Breast cancer research and treatment 2002;76(2):125-30.
2002: Keyomarsi Khandan; Tucker Susan L; Buchholz Thomas A; Callister Matthew; Ding Ye; Hortobagyi Gabriel N; Bedrosian Isabelle; Knickerbocker Christopher; Toyofuku Wendy; Lowe Michael; Herliczek Thaddeus W; Bacus Sarah S
Cyclin E and survival in patients with breast cancer.
The New England journal of medicine 2002;347(20):1566-75.
2002: Murray James L; Gillogly Michael E; Przepiorka Donna; Brewer Hannah; Ibrahim Nuhad K; Booser Daniel J; Hortobagyi Gabriel N; Kudelka Andrzej P; Grabstein Kenneth H; Cheever Martin A; Ioannides Constantin G
Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(11):3407-18.
2002: Giordano Sharon H; Booser Daniel J; Murray James L; Ibrahim Nuhad K; Rahman Zia U; Valero Vicente; Theriault Richard L; Rosales Marguerite F; Rivera Edgardo; Frye Debbie; Ewer Michael; Ordonez Nelson G; Buzdar Aman U; Hortobagyi Gabriel N
A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(11):3360-8.
2002: Vlastos Georges; Mirza Nadeem Q; Meric Funda; Hunt Kelly K; Mirza Attiqa N; Newman Lisa A; Ames Frederick C; Kuerer Henry M; Ross Merrick I; Feig Barry; Babiera Gildy; Buchholz Thomas A; Hortobagyi Gabriel N; Singletary S Eva
Breast-conservation therapy in early-stage breast cancer patients with a positive family history.
Annals of surgical oncology 2002;9(9):912-9.
2002: Vassilopoulou-Sellin Rena; Cohen Deborah S; Hortobagyi Gabriel N; Klein Mary Jean; McNeese Marsha; Singletary S Eva; Smith Terry L; Theriault Richard L
Estrogen replacement therapy for menopausal women with a history of breast carcinoma: results of a 5-year, prospective study.
Cancer 2002;95(9):1817-26.
2002: Valero Vicente; Buzdar Aman U; McNeese Marsha; Singletary Eva; Hortobagyi Gabriel N
Primary chemotherapy in the treatment of breast cancer: the University of Texas M. D. Anderson Cancer Center experience.
Clinical breast cancer 2002;3 Suppl 2():S63-8.
2002: Esteva Francisco J; Sahin Aysegul A; Cristofanilli Massimo; Arun Banu; Hortobagyi Gabriel N
Molecular prognostic factors for breast cancer metastasis and survival.
Seminars in radiation oncology 2002;12(4):319-28.
2002: Giordano Sharon H; Buzdar Aman U; Hortobagyi Gabriel N
Breast cancer in men.
Annals of internal medicine 2002;137(8):678-87.
2002: Ding Yi; Wen Yong; Spohn Bill; Wang Li; Xia Weiya; Kwong Ka Yin; Shao Ruping; Li Zheng; Hortobagyi Gabriel N; Hung Mien-Chie; Yan Duen-Hwa
Proapoptotic and antitumor activities of adenovirus-mediated p202 gene transfer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(10):3290-7.
2002: Hortobagyi Gabriel N
The status of breast cancer management: challenges and opportunities.
Breast cancer research and treatment 2002;75 Suppl 1():S61-5; discussion S57-9.
2002: Huang Eugene; McNeese Marsha D; Strom Eric A; Perkins George H; Katz Angela; Hortobagyi Gabriel N; Valero Vicente; Kuerer Henry M; Singletary S Eva; Hunt Kelly K; Buzdar Aman U; Buchholz Thomas A
Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer.
International journal of radiation oncology, biology, physics 2002;53(5):1225-33.
2002: Green Marjorie C; Hortobagyi Gabriel N
Adjuvant chemotherapy for breast cancer.
Langenbeck's archives of surgery / Deutsche Gesellschaft für Chirurgie 2002;387(3-4):109-116.
2002: Green Marjorie; Hortobagyi Gabriel N
Neoadjuvant chemotherapy for operable breast cancer.
Oncology (Williston Park, N.Y.) 2002;16(7):871-84, 889; discussion 889-90, 892-4, 897-8.
2002: Booser Daniel J; Esteva Francisco J; Rivera Edgardo; Valero Vicente; Esparza-Guerra Laura; Priebe Waldemar; Hortobagyi Gabriel N
Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer.
Cancer chemotherapy and pharmacology 2002;50(1):6-8.
2002: Meric Funda; Buchholz Thomas A; Mirza Nadeem Q; Vlastos Georges; Ames Frederick C; Ross Merrick I; Pollock Raphael E; Singletary S Eva; Feig Barry W; Kuerer Henry M; Newman Lisa A; Perkins George H; Strom Eric A; McNeese Marsha D; Hortobagyi Gabriel N; Hunt Kelly K
Long-term complications associated with breast-conservation surgery and radiotherapy.
Annals of surgical oncology 2002;9(6):543-9.
2002: Buchholz Thomas A; Katz Angela; Strom Eric A; McNeese Marsha D; Perkins George H; Hortobagyi Gabriel N; Thames Howard D; Kuerer Henry M; Singletary S Eva; Sahin Aysegul A; Hunt Kelly K; Buzdar Aman U; Valero Vicente; Sneige Nour; Tucker Susan L
Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy.
International journal of radiation oncology, biology, physics 2002;53(4):880-8.
2002: Hortobagyi Gabriel N; Kris Mark G
Expanding horizons: an update on the use of docetaxel in non-small cell lung, ovarian, and breast cancers.
Seminars in oncology 2002;29(3 Suppl 12):1-3.
2002: Hortobagyi Gabriel N
Novel approaches to the management of bone metastases in patients with breast cancer.
Seminars in oncology 2002;29(3 Suppl 11):134-44.
2002: Cristofanilli Massimo; Charnsangavej Chusilp; Hortobagyi Gabriel N
Angiogenesis modulation in cancer research: novel clinical approaches.
Nature reviews. Drug discovery 2002;1(6):415-26.
2002: Wang Jianzhou; Buchholz Thomas A; Middleton Lavinia P; Allred D Craig; Tucker Susan L; Kuerer Henry M; Esteva Francisco J; Hortobagyi Gabriel N; Sahin Aysegul A
Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma.
Cancer 2002;94(12):3107-14.
2002: Hortobagyi Gabriel N
Integration of docetaxel into adjuvant breast cancer treatment regimens.
Oncology (Williston Park, N.Y.) 2002;16(6 Suppl 6):27-33.
2002: Hoque Ashraful; Sneige Nour; Sahin Aysegul A; Menter David G; Bacus James W; Hortobagyi Gabriel N; Lippman Scott M
Her-2/neu gene amplification in ductal carcinoma in situ of the breast.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2002;11(6):587-90.
2002: Esmaeli Bita; Hortobagyi Gabriel N; Esteva Francisco J; Booser Daniel; Ahmadi M Amir; Rivera Edgardo; Arbuckle Rebecca; Delpassand Ebrahim; Guerra Laura; Valero Vicente
Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer.
Ophthalmology 2002;109(6):1188-91.
2002: Giordano Sharon H; Valero Vicente; Buzdar Aman U; Hortobagyi Gabriel N
Efficacy of anastrozole in male breast cancer.
American journal of clinical oncology 2002;25(3):235-7.
2002: Hortobagyi Gabriel N
Gemcitabine in combination with vinorelbine for treatment of advanced breast cancer.
Clinical breast cancer 2002;3 Suppl 1():34-8.
2002: Rivera Edgardo; Valero Vicente; Cristofanilli Massimo; Frye Debra K; Booser Daniel J; Rosales Marguerite M; Hortobagyi Gabriel N
Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma.
Cancer 2002;94(9):2321-6.
2002: Buzdar Aman U; Singletary S Eva; Valero Vicente; Booser Daniel J; Ibrahim Nuhad K; Rahman Zia; Theriault Richard L; Walters Ronald; Rivera Edgardo; Smith Terry L; Holmes Frankie A; Hoy Emma; Frye Debra K; Manuel Nikki; Kau Shu-Wan; McNeese Marsha D; Strom Eric; Thomas Eva; Hunt Kelly; Ames Fred; Berry Donald; Hortobagyi Gabriel N
Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(5):1073-9.
2002: Ibrahim Nuhad K; Desai Neil; Legha Sewa; Soon-Shiong Patrick; Theriault Richard L; Rivera Edgardo; Esmaeli Bita; Ring Sigrid E; Bedikian Agop; Hortobagyi Gabriel N; Ellerhorst Julie A
Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(5):1038-44.
2002: Hortobagyi Gabriel N
The influence of menstrual cycle phase on surgical treatment of primary breast cancer: have we made any progress over the past 13 years?
Journal of the National Cancer Institute 2002;94(9):641-3.
2002: Meric Funda; Hung Mien-Chie; Hortobagyi Gabriel N; Hunt Kelly K
HER2/neu in the management of invasive breast cancer.
Journal of the American College of Surgeons 2002;194(4):488-501.
2002: Esteva Francisco J; Valero Vicente; Booser Daniel; Guerra Laura T; Murray James L; Pusztai Lajos; Cristofanilli Massimo; Arun Banu; Esmaeli Bita; Fritsche Herbert A; Sneige Nour; Smith Terry L; Hortobagyi Gabriel N
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(7):1800-8.
2002: Rivera Edgardo; Valero Vicente; Esteva Francisco J; Syrewicz Laura; Cristofanilli Massimo; Rahman Zia; Booser Daniel J; Hortobagyi Gabriel N
Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer.
Cancer chemotherapy and pharmacology 2002;49(4):299-302.
2002: Arun B; Hortobagyi G N
Progress in breast cancer chemoprevention.
Endocrine-related cancer 2002;9(1):15-32.
2002: Esmaeli B; Hortobagyi G; Esteva F; Valero V; Ahmadi M A; Booser D; Ibrahim N; Delpassand E; Arbuckle R
Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(2):218-21.
2002: Rivera Edgardo; Sutton Linda; Colwell Bruce; Graham Mark; Frye Debra; Somerville Matt; Conklin Heather S; McGuirt Chip; Levin Jeremey; Hortobagyi Gabriel N
Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(4):987-93.
2002: Cristofanilli Massimo; De Gasperis Giovanni; Zhang Lisha; Hung Mien-Chie; Gascoyne Peter R C; Hortobagyi Gabriel N
Automated electrorotation to reveal dielectric variations related to HER-2/neu overexpression in MCF-7 sublines.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(2):615-9.
2002: Hortobagyi Gabriel N
Can we cure limited metastatic breast cancer?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(3):620-3.
2002: Rivera Edgardo; Holmes Frankie A; Buzdar Aman U; Asmar Lina; Kau Shu-Wan; Fraschini Giuseppe; Walters Ronald; Theriault Richard L; Hortobagyi Gabriel N
Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease.
The breast journal 2002;8(1):2-9.
2002: Buchholz Thomas A; Tucker Susan L; Masullo Lawrence; Kuerer Henry M; Erwin Jessica; Salas Jessica; Frye Debbie; Strom Eric A; McNeese Marsha D; Perkins George; Katz Angela; Singletary S Eva; Hunt Kelly K; Buzdar Aman U; Hortobagyi Gabriel N
Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):17-23.
2002: Ibrahim Nuhad K; Rahman Zia; Valero Vicente; Murray James L; Frye Debra; Hortobagyi Gabriel N
Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer.
Cancer investigation 2002;20(1):29-37.
2001: Sneige N; Kemp B; Pusztai L; Asmar L; Hortobagyi G N
Chemotherapy-induced histologic changes in mastectomy specimens and their potential significance.
Breast (Edinburgh, Scotland) 2001;10(6):492-500.
2001: Kuerer H M; Singletary S E; Buzdar A U; Ames F C; Valero V; Buchholz T A; Ross M I; Pusztai L; Hortobagyi G N; Hunt K K
Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma.
American journal of surgery 2001;182(6):601-8.
2001: Hortobagyi G N
Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.
Seminars in oncology 2001;28(6 Suppl 18):43-7.
2001: Wang S C; Zhang L; Hortobagyi G N; Hung M C
Targeting HER2: recent developments and future directions for breast cancer patients.
Seminars in oncology 2001;28(6 Suppl 18):21-9.
2001: Xiong Q; Valero V; Kau V; Kau S W; Taylor S; Smith T L; Buzdar A U; Hortobagyi G N; Theriault R L
Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience.
Cancer 2001;92(10):2523-8.
2001: Cristofanilli M; Buzdar A U; Sneige N; Smith T; Wasaff B; Ibrahim N; Booser D; Rivera E; Murray J L; Valero V; Ueno N; Singletary E S; Hunt K; Strom E; McNeese M; Stelling C; Hortobagyi G N
Paclitaxel in the multimodality treatment for inflammatory breast carcinoma.
Cancer 2001;92(7):1775-82.
2001: Hortobagyi G N; Perez E A
Integration of trastuzumab into adjuvant systemic therapy of breast cancer: ongoing and planned clinical trials.
Seminars in oncology 2001;28(5 Suppl 16):41-6.
2001: Hortobagyi G N
Optimal duration of therapy with trastuzumab.
Seminars in oncology 2001;28(5 Suppl 16):33-40.
2001: Buchholz T A; Hill B S; Tucker S L; Frye D K; Kuerer H M; Buzdar A U; McNeese M D; Singletary S E; Ueno N T; Pusztai L; Valero V; Hortobagyi G N
Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy.
Cancer journal (Sudbury, Mass.) 2001;7(5):413-20.
2001: Vlastos G; Mirza N Q; Meric F; Hunt K K; Kuerer H M; Ames F C; Ross M I; Buchholz T A; Hortobagyi G N; Singletary S E
Breast conservation therapy as a treatment option for the elderly. The M. D. Anderson experience.
Cancer 2001;92(5):1092-100.
2001: Ali S M; Esteva F J; Hortobagyi G; Harvey H; Seaman J; Knight R; Costa L; Lipton A
Safety and efficacy of bisphosphonates beyond 24 months in cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(14):3434-7.
2001: Hortobagyi G N; Ueno N T; Xia W; Zhang S; Wolf J K; Putnam J B; Weiden P L; Willey J S; Carey M; Branham D L; Payne J Y; Tucker S D; Bartholomeusz C; Kilbourn R G; De Jager R L; Sneige N; Katz R L; Anklesaria P; Ibrahim N K; Murray J L; Theriault R L; Valero V; Gershenson D M; Bevers M W; Huang L; Lopez-Berestein G; Hung M C
Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(14):3422-33.
2001: Hortobagyi G N
Adjuvant systemic therapy for early breast cancer: progress and controversies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(7):1839-42.
2001: Theriault R L; Hortobagyi G N
The evolving role of bisphosphonates.
Seminars in oncology 2001;28(3):284-90.
2001: Seidman A D; Fornier M N; Esteva F J; Tan L; Kaptain S; Bach A; Panageas K S; Arroyo C; Valero V; Currie V; Gilewski T; Theodoulou M; Moynahan M E; Moasser M; Sklarin N; Dickler M; D'Andrea G; Cristofanilli M; Rivera E; Hortobagyi G N; Norton L; Hudis C A
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(10):2587-95.
2001: Hortobagyi G N
Unmet needs in metastatic bone disease and its complications: is progress possible?
Seminars in oncology 2001;28(2 Suppl 6):1-3.
2001: Buchholz T A; Tucker S L; Erwin J; Mathur D; Strom E A; McNeese M D; Hortobagyi G N; Cristofanilli M; Esteva F J; Newman L; Singletary S E; Buzdar A U; Hunt K K
Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(8):2240-6.
2001: Rivera E; Valero V; Syrewicz L; Rahman Z; Esteva F J; Theriault R L; Rosales M M; Booser D; Murray J L; Bast R C; Hortobagyi G N;
Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(6):1716-22.
2001: Hortobagyi G N
Treatment of advanced breast cancer with gemcitabine and vinorelbine.
Oncology (Williston Park, N.Y.) 2001;15(2 Suppl 3):15-7.
2001: Ibrahim N K; Buzdar A U; Valero V; Dhingra K; Willey J; Hortobagyi G N
Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma.
Cancer 2001;91(4):664-71.
2001: Brito R A; Valero V; Buzdar A U; Booser D J; Ames F; Strom E; Ross M; Theriault R L; Frye D; Kau S W; Asmar L; McNeese M; Singletary S E; Hortobagyi G N
Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(3):628-33.
2001: Cristofanilli M; Hortobagyi G N
New horizons in treating metastatic disease.
Clinical breast cancer 2001;1(4):276-87.
2001: Hortobagyi G N
Progress in systemic chemotherapy of primary breast cancer: an overview.
Journal of the National Cancer Institute. Monographs 2001;(30):72-9.
2001: Ibrahim N K; Valero V; Rahman Z; Theriault R L; Walters R S; Buzdar A U; Booser D J; Holmes F A; Murray J L; Willey J; Bast R; Hortobagyi G N
Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation.
Cancer investigation 2001;19(5):459-66.
2000: Perez E A; Hortobagyi G N
Ongoing and planned adjuvant trials with trastuzumab.
Seminars in oncology 2000;27(6 Suppl 11):26-32; discussion 92-100.
2000: Ibrahim N K; Buzdar A U; Asmar L; Theriault R L; Hortobagyi G N
Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M.D. Anderson experience, with long-term follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(12):1597-601.
2000: Rivera E; Holmes F A; Frye D; Valero V; Theriault R L; Booser D; Walters R; Buzdar A U; Dhingra K; Fraschini G; Hortobagyi G N
Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy.
Cancer 2000;89(11):2195-201.
2000: Michaud L B; Valero V; Hortobagyi G
Risks and benefits of taxanes in breast and ovarian cancer.
Drug safety : an international journal of medical toxicology and drug experience 2000;23(5):401-28.
2000: Freedman L M; Buchholz T A; Thames H D; Strom E A; McNeese M D; Hortobagyi G N; Singletary S E; Heaton K M; Hunt K K
Local-regional control in breast cancer patients with a possible genetic predisposition.
International journal of radiation oncology, biology, physics 2000;48(4):951-7.
2000: Mirza N Q; Vlastos G; Meric F; Sahin A A; Singletary S E; Newman L A; Kuerer H M; Ames F C; Ross M I; Feig B W; Pollock R E; Buchholz T A; McNeese M D; Strom E A; Hortobagyi G N; Hunt K K
Ductal carcinoma-in-situ: long-term results of breast-conserving therapy.
Annals of surgical oncology 2000;7(9):656-64.
2000: Breslin T M; Cohen L; Sahin A; Fleming J B; Kuerer H M; Newman L A; Delpassand E S; House R; Ames F C; Feig B W; Ross M I; Singletary S E; Buzdar A U; Hortobagyi G N; Hunt K K
Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(20):3480-6.
2000: Katz A; Strom E A; Buchholz T A; Thames H D; Smith C D; Jhingran A; Hortobagyi G; Buzdar A U; Theriault R; Singletary S E; McNeese M D
Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(15):2817-27.
2000: Green M C; Murray J L; Hortobagyi G N
Monoclonal antibody therapy for solid tumors.
Cancer treatment reviews 2000;26(4):269-86.
2000: Meric F; Mirza N Q; Buzdar A U; Hunt K K; Ames F C; Ross M I; Pollock R E; Newman L A; Feig B W; Strom E A; Buchholz T A; McNeese M D; Hortobagyi G N; Singletary S E
Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T3N0M0 breast cancer.
Annals of surgical oncology 2000;7(6):435-40.
2000: Hortobagyi G N
Developments in chemotherapy of breast cancer.
Cancer 2000;88(12 Suppl):3073-9.
2000: Hoff P M; Valero V; Buzdar A U; Singletary S E; Theriault R L; Booser D; Asmar L; Frye D; McNeese M D; Hortobagyi G N
Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy.
Cancer 2000;88(9):2054-60.
2000: Ibrahim N K; Valero V; Theriault R L; Willey J; Walters R S; Buzdar A U; Booser D J; Hortobagyi G N
Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer.
American journal of clinical oncology 2000;23(2):117-21.
2000: Pivot X; Asmar L; Hortobagyi G N; Theriault R; Pastorini F; Buzdar A
A retrospective study of first indicators of breast cancer recurrence.
Oncology 2000;58(3):185-90.
2000: Lipton A; Theriault R L; Hortobagyi G N; Simeone J; Knight R D; Mellars K; Reitsma D J; Heffernan M; Seaman J J
Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.
Cancer 2000;88(5):1082-90.
2000: Gale R P; Park R E; Dubois R; Bitran J D; Buzdar A; Hortobagyi G; Jones S E; Lazar G S; Spitzer G; Swain S M; Vaughn C B; Vogel C E; Martino S
Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer.
Clinical transplantation 2000;14(1):32-41.
2000: Booser D J; Walters R S; Holmes F A; Hortobagyi G N
Continuous-infusion high-dose leucovorin with 5-fluorouracil and cisplatin for relapsed metastatic breast cancer: a phase II study.
American journal of clinical oncology 2000;23(1):40-1.
2000: Pivot X; Asmar L; Buzdar A U; Valero V; Hortobagyi G
A unified definition of clinical anthracycline resistance breast cancer.
British journal of cancer 2000;82(3):529-34.
2000: Dixon J M; Hortobagyi G
Treating young patients with breast cancer. The evidence suggests that all should be treated with adjuvant therapy.
BMJ (Clinical research ed.) 2000;320(7233):457-8.
2000: Hortobagyi G N; Buzdar A U; Theriault R L; Valero V; Frye D; Booser D J; Holmes F A; Giralt S; Khouri I; Andersson B; Gajewski J L; Rondon G; Smith T L; Singletary S E; Ames F C; Sneige N; Strom E A; McNeese M D; Deisseroth A B; Champlin R E
Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma.
Journal of the National Cancer Institute 2000;92(3):225-33.
2000: Ibrahim N K; Sahin A A; Dubrow R A; Lynch P M; Boehnke-Michaud L; Valero V; Buzdar A U; Hortobagyi G N
Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer.
Lancet 2000;355(9200):281-3.
2000: Buchholz T A; Tucker S L; Moore R A; McNeese M D; Strom E A; Jhingrin A; Hortobagyi G N; Singletary S E; Champlin R E
Importance of radiation therapy for breast cancer patients treated with high-dose chemotherapy and stem cell transplant.
International journal of radiation oncology, biology, physics 2000;46(2):337-43.
2000: Major P P; Lipton A; Berenson J; Hortobagyi G
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Cancer 2000;88(1):6-14.
2000: Booser D J; Perez-Soler R; Cossum P; Esparza-Guerra L; Wu Q P; Zou Y; Priebe W; Hortobagyi G N
Phase I study of liposomal annamycin.
Cancer chemotherapy and pharmacology 2000;46(5):427-32.
2000: Esteva F J; Soh L T; Holmes F A; Plunkett W; Meyers C A; Forman A D; Hortobagyi G N
Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer.
Cancer chemotherapy and pharmacology 2000;46(5):382-6.
2000: Hung M C; Hortobagyi G N; Ueno N T
Development of clinical trial of E1A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer.
Advances in experimental medicine and biology 2000;465():171-80.
2000: Hortobagyi G
Adjuvant therapy for breast cancer.
Annual review of medicine 2000;51():377-92.
1999: Lenert J T; Vlastos G; Mirza N Q; Winchester D J; Binkley S M; Ames F C; Ross M I; Feig B W; Hunt K K; Strom E; Buzdar A U; Hortobagyi G N; Singletary S E
Primary tumor response to induction chemotherapy as a predictor of histological status of axillary nodes in operable breast cancer patients.
Annals of surgical oncology 1999;6(8):762-7.
1999: Hortobagyi G N
High-dose chemotherapy for primary breast cancer: facts versus anecdotes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(11 Suppl):25-9.
1999: Buzdar A U; Singletary S E; Theriault R L; Booser D J; Valero V; Ibrahim N; Smith T L; Asmar L; Frye D; Manuel N; Kau S W; McNeese M; Strom E; Hunt K; Ames F; Hortobagyi G N
Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(11):3412-7.
1999: Esteva F J; Hortobagyi G N
Adjuvant systemic therapy for primary breast cancer.
The Surgical clinics of North America 1999;79(5):1075-90.
1999: Pusztai L; Esteva F J; Cristofanilli M; Hung M C; Hortobagyi G N
Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer.
Cancer treatment reviews 1999;25(5):271-7.
1999: Ibrahim N K; Rahman Z; Valero V; Willey J; Theriault R L; Buzdar A U; Murray J L; Bast R; Hortobagyi G N
Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma.
Cancer 1999;86(7):1251-7.
1999: Ibrahim N K; Hortobagyi G N
The evolving role of specific estrogen receptor modulators (SERMs)
Surgical oncology 1999;8(2):103-23.
1999: Buzdar A U; Hortobagyi G N
Recent advances in adjuvant therapy of breast cancer.
Seminars in oncology 1999;26(4 Suppl 12):21-7.
1999: Hortobagyi G N; Hung M C; Buzdar A U
Recent developments in breast cancer therapy.
Seminars in oncology 1999;26(4 Suppl 12):11-20.
1999: Pivot X; Asmar L; Hortobagyi G N
The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer (Review).
International journal of oncology 1999;15(2):381-6.
1999: Kuerer H M; Sahin A A; Hunt K K; Newman L A; Breslin T M; Ames F C; Ross M I; Buzdar A U; Hortobagyi G N; Singletary S E
Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.
Annals of surgery 1999;230(1):72-8.
1999: Hortobagyi G N
Recent progress in the clinical development of docetaxel (Taxotere).
Seminars in oncology 1999;26(3 Suppl 9):32-6.
1999: Pusztai L; Asmar L; Smith T L; Hortobagyi G N
Relapse after complete response to anthracycline-based combination chemotherapy in metastatic breast cancer.
Breast cancer research and treatment 1999;55(1):1-8.
1999: Buchholz T A; Hunt K K; Amosson C M; Tucker S L; Strom E A; McNeese M D; Buzdar A U; Singletary S E; Hortobagyi G N
Sequencing of chemotherapy and radiation in lymph node-negative breast cancer.
The cancer journal from Scientific American 1999;5(3):159-64.
1999: Vassilopoulou-Sellin R; Asmar L; Hortobagyi G N; Klein M J; McNeese M; Singletary S E; Theriault R L
Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(5):1482-7.
1999: Valero V; Buzdar A U; Theriault R L; Azarnia N; Fonseca G A; Willey J; Ewer M; Walters R S; Mackay B; Podoloff D; Booser D; Lee L W; Hortobagyi G N
Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(5):1425-34.
1999: Cristofanilli M; Holmes F A; Esparza L; Valero V; Buzdar A U; Neidhart J A; Hortobagyi G N
Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience.
Breast cancer research and treatment 1999;54(3):225-33.
1999: Holmes F A; Valero V; Walters R S; Theriault R L; Booser D J; Gibbs H; Fraschini G; Buzdar A U; Willey J; Frye D; Asmar L; Hortobagyi G N
Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(4):403-11.
1999: Esteva F J; Hortobagyi G N
Locally advanced breast cancer.
Hematology/oncology clinics of North America 1999;13(2):457-72, vii.
1999: Berry D L; Theriault R L; Holmes F A; Parisi V M; Booser D J; Singletary S E; Buzdar A U; Hortobagyi G N
Management of breast cancer during pregnancy using a standardized protocol.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(3):855-61.
1999: Theriault R L; Lipton A; Hortobagyi G N; Leff R; Glück S; Stewart J F; Costello S; Kennedy I; Simeone J; Seaman J J; Knight R D; Mellars K; Heffernan M; Reitsma D J
Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(3):846-54.
1999: Kuerer H M; Newman L A; Smith T L; Ames F C; Hunt K K; Dhingra K; Theriault R L; Singh G; Binkley S M; Sneige N; Buchholz T A; Ross M I; McNeese M D; Buzdar A U; Hortobagyi G N; Singletary S E
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(2):460-9.
1999: Zhang L; Lau Y K; Xia W; Hortobagyi G N; Hung M C
Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(2):343-53.
1999: Rahman Z U; Frye D K; Smith T L; Asmar L; Theriault R L; Buzdar A U; Hortobagyi G N
Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference.
Cancer 1999;85(1):104-11.
1999: Ibrahim N K; Hortobagyi G N; Ewer M; Ali M K; Asmar L; Theriault R L; Fraschini G; Frye D K; Buzdar A U
Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience.
Cancer chemotherapy and pharmacology 1999;43(6):471-8.
1999: Pusztai L; Holmes F A; Fraschini G; Hortobagyi G N
Phase II study of mitoxantrone by 14-day continuous infusion with granulocyte colony-stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy.
Cancer chemotherapy and pharmacology 1999;43(1):86-91.
1998: Lipton A; Demers L; Curley E; Chinchilli V; Gaydos L; Hortobagyi G; Theriault R; Clemens D; Costa L; Seaman J; Knight R
Markers of bone resorption in patients treated with pamidronate.
European journal of cancer (Oxford, England : 1990) 1998;34(13):2021-6.
1998: Kuerer H M; Newman L A; Buzdar A U; Hunt K K; Dhingra K; Buchholz T A; Binkley S M; Ames F C; Feig B W; Ross M I; Hortobagyi G N; Singletary S E
Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer.
American journal of surgery 1998;176(6):502-9.
1998: Kuerer H M; Newman L A; Fornage B D; Dhingra K; Hunt K K; Buzdar A U; Ames F C; Ross M I; Feig B W; Hortobagyi G N; Singletary S E
Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer.
Annals of surgical oncology 1998;5(8):673-80.
1998: Hortobagyi G
An expanding role for docetaxel.
Seminars in oncology 1998;25(6 Suppl 13):1-3.
1998: Cristofanilli M; Hortobagyi G N
Current methods to prevent the development of breast cancer.
In vivo (Athens, Greece) 1998;12(6):659-65.
1998: Cristofanilli M; Bryan W J; Miller L L; Chang A Y; Gradishar W J; Kufe D W; Hortobagyi G N
Phase II study of adozelesin in untreated metastatic breast cancer.
Anti-cancer drugs 1998;9(9):779-82.
1998: Pusztai L; Walters R S; Valero V; Theriault R L; Hortobagyi G N
Daily oral etoposide in patients with heavily pretreated metastatic breast cancer.
American journal of clinical oncology 1998;21(5):442-6.
1998: Valero V; Jones S E; Von Hoff D D; Booser D J; Mennel R G; Ravdin P M; Holmes F A; Rahman Z; Schottstaedt M W; Erban J K; Esparza-Guerra L; Earhart R H; Hortobagyi G N; Burris H A
A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(10):3362-8.
1998: Hortobagyi G N
Treatment of breast cancer.
The New England journal of medicine 1998;339(14):974-84.
1998: Rahman Z U; Hortobagyi G N; Buzdar A U; Champlin R
High-dose chemotherapy with autologous stem cell support in patients with breast cancer.
Cancer treatment reviews 1998;24(4):249-63.
1998: Hortobagyi G N; Hung M C; Lopez-Berestein G
A Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer.
Human gene therapy 1998;9(12):1775-98.
1998: Pusztai L; Hortobagyi G N
Discouraging news for high-dose chemotherapy in high-risk breast cancer.
Lancet 1998;352(9127):501-2.
1998: Walters R S; Holmes F A; Valero V; Esparza-Guerra L; Hortobagyi G N
Phase II study of ifosfamide and mesna in patients with metastatic breast cancer.
American journal of clinical oncology 1998;21(4):413-5.
1998: Kuerer H M; Newman L A; Buzdar A U; Dhingra K; Hunt K K; Buchholz T A; Binkley S M; Strom E A; Ames F C; Ross M I; Feig B W; McNeese M D; Hortobagyi G N; Singletary S E
Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.
The cancer journal from Scientific American 1998;4(4):230-6.
1998: Hortobagyi G N
Progress in endocrine therapy for breast carcinoma.
Cancer 1998;83(1):1-6.
1998: Zhang L; Lau Y K; Xi L; Hong R L; Kim D S; Chen C F; Hortobagyi G N; Chang C; Hung M C
Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties.
Oncogene 1998;16(22):2855-63.
1998: Hortobagyi G N; Theriault R L; Lipton A; Porter L; Blayney D; Sinoff C; Wheeler H; Simeone J F; Seaman J J; Knight R D; Heffernan M; Mellars K; Reitsma D J
Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(6):2038-44.
1998: Diaz-Canton E A; Valero V; Rahman Z; Rodriguez-Monge E; Frye D; Smith T; Buzdar A U; Hortobagyi G N
Clinical course of breast cancer patients with metastases confined to the lungs treated with chemotherapy. The University of Texas M.D. Anderson Cancer Center experience and review of the literature.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(4):413-8.
1998: Yu D; Liu B; Jing T; Sun D; Price J E; Singletary S E; Ibrahim N; Hortobagyi G N; Hung M C
Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol.
Oncogene 1998;16(16):2087-94.
1998: Dhingra K; Sahin A; Emami K; Hortobagyi G N; Estrov Z
Expression of leukemia inhibitory factor and its receptor in breast cancer: a potential autocrine and paracrine growth regulatory mechanism.
Breast cancer research and treatment 1998;48(2):165-74.
1998: Buzdar A U; Hortobagyi G
Update on endocrine therapy for breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(3):527-34.
1998: Ueno N T; Rondón G; Mirza N Q; Geisler D K; Anderlini P; Giralt S A; Andersson B S; Claxton D F; Gajewski J L; Khouri I F; Körbling M; Mehra R C; Przepiorka D; Rahman Z; Samuels B I; van Besien K; Hortobagyi G N; Champlin R E
Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(3):986-93.
1998: Hoff P M; Valero V; Ibrahim N; Willey J; Hortobagyi G N
Hand-foot syndrome following prolonged infusion of high doses of vinorelbine.
Cancer 1998;82(5):965-9.
1998: Hortobagyi G N; Buzdar A U
Anastrozole (Arimidex), a new aromatase inhibitor for advanced breast cancer: mechanism of action and role in management.
Cancer investigation 1998;16(6):385-90.
1997: Kinney A Y; Sahin A; Vernon S W; Frankowski R F; Annegers J F; Hortobagyi G N; Buzdar A U; Frye D K; Dhingra K
The prognostic significance of sialyl-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy.
Cancer 1997;80(12):2240-9.
1997: Hudis C; Riccio L; Holmes F; Seidman A; Baselga J; Currie V; Fennelly D; Gilewski T; Moynahan M; Raptis G; Sklarin N; Surbone A; Uhlenhopp M; Maickel N; Yao T J; Hellmann S; Usakewicz J; Hortobagyi G; Norton L
Phase II study of semisynthetic paclitaxel in metastatic breast cancer.
European journal of cancer (Oxford, England : 1990) 1997;33(13):2198-202.
1997: Xu X C; Sneige N; Liu X; Nandagiri R; Lee J J; Lukmanji F; Hortobagyi G; Lippman S M; Dhingra K; Lotan R
Progressive decrease in nuclear retinoic acid receptor beta messenger RNA level during breast carcinogenesis.
Cancer research 1997;57(22):4992-6.
1997: Rahman Z; Champlin R; Rondon G; Frye D; Valero V; Mehra R; Hortobagyi G
Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
Seminars in oncology 1997;24(5 Suppl 17):S17-77-S17-80.
1997: Hortobagyi G N; Willey J; Rahman Z; Holmes F A; Theriault R L; Buzdar A U
Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer.
Seminars in oncology 1997;24(5 Suppl 17):S17-65-S17-68.
1997: Buzdar A U; Hortobagyi G N; Asmar L; Theriault R L; Rahman Z; McNeese M; Singletary S; Ames F
Prospective randomized trial of paclitaxel alone versus 5-fluorouracil/doxorubicin/cyclophosphamide as induction therapy in patients with operable breast cancer.
Seminars in oncology 1997;24(5 Suppl 17):S17-31-S17-34.
1997: Hortobagyi G N
Chemotherapy of breast cancer: a historical perspective.
Seminars in oncology 1997;24(5 Suppl 17):S17-1-S17-4.
1997: Rahman Z U; Frye D K; Buzdar A U; Smith T L; Asmar L; Champlin R E; Hortobagyi G N
Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(10):3171-7.
1997: Holmes F A; Lopez A; Mavligit G; Fraschini G; Frye D; Hortobagyi G N
Secondary drug resistance in breast cancer: failure to reverse with oral nifedipine.
International journal of cancer. Journal international du cancer 1997;73(2):184-6.
1997: Herrada J; Iyer R B; Atkinson E N; Sneige N; Buzdar A U; Hortobagyi G N
Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(9):1565-9.
1997: Buzdar A U; Asmar L; Hortobagyi G N
Impact of patient characteristics on treatment outcome: anthracycline resistance.
European journal of cancer (Oxford, England : 1990) 1997;33 Suppl 7():S3-6.
1997: Hortobagyi G N
Docetaxel: today's results and tomorrow's promises.
Oncology (Williston Park, N.Y.) 1997;11(8 Suppl 8):11-4.
1997: Hortobagyi G N
Introduction: taxoids and the management of breast cancer.
Seminars in oncology 1997;24(4 Suppl 13):S13-1-S13-2.
1997: Hortobagyi G N; Holmes F A; Theriault R L; Rahman Z; Buzdar A U
Combination chemotherapy with paclitaxel and doxorubicin for metastatic breast cancer.
Seminars in oncology 1997;24(4 Suppl 11):S11-13-S11-19.
1997: Chan D W; Beveridge R A; Muss H; Fritsche H A; Hortobagyi G; Theriault R; Kiang D; Kennedy B J; Evelegh M
Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(6):2322-8.
1997: Hortobagyi G N
Paclitaxel-based combination chemotherapy for breast cancer.
Oncology (Williston Park, N.Y.) 1997;11(3 Suppl 2):29-37.
1997: Rahman Z; Esparza-Guerra L; Yap H Y; Fraschini G; Bodey G; Hortobagyi G
Chemotherapy-induced neutropenia and fever in patients with metastatic breast carcinoma receiving salvage chemotherapy.
Cancer 1997;79(6):1150-7.
1997: Hortobagyi G N; Holmes F A; Ibrahim N; Champlin R; Buzdar A U
The University of Texas M.D. Anderson Cancer Center experience with paclitaxel in breast cancer.
Seminars in oncology 1997;24(1 Suppl 3):S30-3.
1997: Hortobagyi G N; Holmes F A
Optimal dosing of paclitaxel and doxorubicin in metastatic breast cancer.
Seminars in oncology 1997;24(1 Suppl 3):S4-7.
1997: Chang J Y; Xia W; Shao R; Sorgi F; Hortobagyi G N; Huang L; Hung M C
The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
Oncogene 1997;14(5):561-8.
1997: Ueno N T; Buzdar A U; Singletary S E; Ames F C; McNeese M D; Holmes F A; Theriault R L; Strom E A; Wasaff B J; Asmar L; Frye D; Hortobagyi G N
Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center.
Cancer chemotherapy and pharmacology 1997;40(4):321-9.
1996: Hanania E G; Giles R E; Kavanagh J; Fu S Q; Ellerson D; Zu Z; Wang T; Su Y; Kudelka A; Rahman Z; Holmes F; Hortobagyi G; Claxton D; Bachier C; Thall P; Cheng S; Hester J; Ostrove J M; Bird R E; Chang A; Korbling M; Seong D; Cote R; Holzmayer T; Deisseroth A B
Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(26):15346-51.
1996: Hortobagyi G N; Theriault R L; Porter L; Blayney D; Lipton A; Sinoff C; Wheeler H; Simeone J F; Seaman J; Knight R D
Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
The New England journal of medicine 1996;335(24):1785-91.
1996: Anderson C M; Walters R S; Hortobagyi G N
Mediastinitis related to probable central vinblastine extravasation in a woman undergoing adjuvant chemotherapy for early breast cancer.
American journal of clinical oncology 1996;19(6):566-8.
1996: Hortobagyi G N; Piccart-Gebhart M J
Current management of advanced breast cancer.
Seminars in oncology 1996;23(5 Suppl 11):1-5.
1996: Diamandidou E; Buzdar A U; Smith T L; Frye D; Witjaksono M; Hortobagyi G N
Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(10):2722-30.
1996: Holmes F A; Madden T; Newman R A; Valero V; Theriault R L; Fraschini G; Walters R S; Booser D J; Buzdar A U; Willey J; Hortobagyi G N
Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(10):2713-21.
1996: Buzdar A U; Plourde P V; Hortobagyi G N
Aromatase inhibitors in metastatic breast cancer.
Seminars in oncology 1996;23(4 Suppl 9):28-32.
1996: Dhingra K; Hortobagyi G N
Critical evaluation of prognostic factors.
Seminars in oncology 1996;23(4):436-45.
1996: Greenberg P A; Hortobagyi G N; Smith T L; Ziegler L D; Frye D K; Buzdar A U
Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(8):2197-205.
1996: Ibrahim N K; Frye D K; Buzdar A U; Walters R S; Hortobagyi G N
Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome.
Archives of internal medicine 1996;156(8):882-8.
1996: Hunt K K; Ames F C; Singletary S E; Buzdar A U; Hortobagyi G N
Locally advanced noninflammatory breast cancer.
The Surgical clinics of North America 1996;76(2):393-410.
1996: Deisseroth A B; Holmes F; Hortobagyi G; Champlin R
Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of breast cancer: a pilot trial.
Human gene therapy 1996;7(3):401-16.
1996: Hortobagyi G N; Ibrahim N
Paclitaxel-containing combination chemotherapy for metastatic breast cancer.
Seminars in oncology 1996;23(1 Suppl 1):53-7.
1996: Hortobagyi G N; Holmes F A
Single-agent paclitaxel for the treatment of breast cancer: an overview.
Seminars in oncology 1996;23(1 Suppl 1):4-9.
1996: Chen T; Dhingra K; Sahin A; Sneige N; Hortobagyi G; Aldaz C M
Technical approach for the study of the genetic evolution of breast cancer from paraffin-embedded tissue sections.
Breast cancer research and treatment 1996;39(2):177-85.
1996: Theriault R L; Walters R S; Holmes F A; Esparza-Guerra L; Kowal C; Hortobagyi G N
A phase II study of CI-973 [SP-4-3(R)]-1,1-cyclobutane-dicarboxylato (2-)] (2-methyl-1,4-butanediamine-N, N') platinum in patients with refractory advanced breast cancer.
Cancer chemotherapy and pharmacology 1996;38(3):289-91.
1996: Hoffman K; Holmes F A; Fraschini G; Esparza L; Frye D; Raber M N; Newman R A; Hortobagyi G N
Phase I-II study: triciribine (tricyclic nucleoside phosphate) for metastatic breast cancer.
Cancer chemotherapy and pharmacology 1996;37(3):254-8.
1995: Valero V; Holmes F A; Walters R S; Theriault R L; Esparza L; Fraschini G; Fonseca G A; Bellet R E; Buzdar A U; Hortobagyi G N
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(12):2886-94.
1995: Hanania E G; Kavanagh J; Hortobagyi G; Giles R E; Champlin R; Deisseroth A B
Recent advances in the application of gene therapy to human disease.
The American journal of medicine 1995;99(5):537-52.
1995: Buzdar A U; Singletary S E; Booser D J; Frye D K; Wasaff B; Hortobagyi G N
Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience.
Surgical oncology clinics of North America 1995;4(4):715-34.
1995: Singletary S E; Hortobagyi G N; Kroll S S
Surgical and medical management of local-regional treatment failures in advanced primary breast cancer.
Surgical oncology clinics of North America 1995;4(4):671-84.
1995: Hortobagyi G N
Management of breast cancer: status and future trends.
Seminars in oncology 1995;22(5 Suppl 12):101-7.
1995: Hortobagyi G N
Innovative approaches to breast cancer treatment: the role of paclitaxel. Introduction.
Seminars in oncology 1995;22(4 Suppl 8):1-2.
1995: Buzdar A U; Holmes F A; Hortobagyi G N
Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience.
Seminars in oncology 1995;22(3 Suppl 6):101-4.
1995: Hortobagyi G N
Future directions for vinorelbine (Navelbine).
Seminars in oncology 1995;22(2 Suppl 5):80-6; discussion 86-7.
1995: Jaiyesimi I A; Buzdar A U; Decker D A; Hortobagyi G N
Use of tamoxifen for breast cancer: twenty-eight years later.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(2):513-29.
1994: Cho S H; Sahin A; Hortobagyi G N; Hittelman W N; Dhingra K
Sialyl-Tn antigen expression occurs early during human mammary carcinogenesis and is associated with high nuclear grade and aneuploidy.
Cancer research 1994;54(24):6302-5.
1994: Hortobagyi G N; Holmes F A; Theriault R L; Buzdar A U
Use of Taxol (paclitaxel) in breast cancer.
Oncology 1994;51 Suppl 1():29-32.
1994: Beitsch P; Lotzová E; Hortobagyi G; Pollock R
Natural immunity in breast cancer patients during neoadjuvant chemotherapy and after surgery.
Surgical oncology 1994;3(4):211-9.
1994: Hortobagyi G N
Multidisciplinary management of advanced primary and metastatic breast cancer.
Cancer 1994;74(1 Suppl):416-23.
1994: Dhingra K; Sneige N; Pandita T K; Johnston D A; Lee J S; Emami K; Hortobagyi G N; Hittelman W N
Quantitative analysis of chromosome in situ hybridization signal in paraffin-embedded tissue sections.
Cytometry 1994;16(2):100-12.
1994: Buzdar A U; Hortobagyi G N; Frye D; Ho D; Booser D J; Valero V; Holmes F A; Birmingham B K; Bui K; Yeh C
Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(1):50-4.
1994: Buzdar A U; Kau S; Hortobagyi G N; Theriault R L; Booser D; Holmes F A; Walters R; Krakoff I H
Phase I trial of droloxifene in patients with metastatic breast cancer.
Cancer chemotherapy and pharmacology 1994;33(4):313-6.
1994: Dhingra K; Valero V; Gutierrez L; Theriault R; Booser D; Holmes F; Buzdar A; Fraschini G; Hortobagyi G
Phase II study of deoxyspergualin in metastatic breast cancer.
Investigational new drugs 1994;12(3):235-41.
1993: Nieweg O E; Wong W H; Singletary S E; Hortobagyi G N; Kim E E
Positron emission tomography of glucose metabolism in breast cancer. Potential for tumor detection, staging, and evaluation of chemotherapy.
Annals of the New York Academy of Sciences 1993;698():423-8.
1993: Buzdar A U; Kau S W; Smith T L; Ames F; Singletary E; Strom E; McNeese M; Hortobagyi G N
The order of administration of chemotherapy and radiation and its effect on the local control of operable breast cancer.
Cancer 1993;71(11):3680-4.
1993: Nieweg O E; Kim E E; Wong W H; Broussard W F; Singletary S E; Hortobagyi G N; Tilbury R S
Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer.
Cancer 1993;71(12):3920-5.
1993: Hortobagyi G N
Mitomycin: its evolving role in the treatment of breast cancer.
Oncology 1993;50 Suppl 1():1-8.
1993: Theriault R L; Fraschini G; Holmes F A; Frye D; Gutterman J U; Hortobagyi G N
The myeloprotective effect of recombinant human granulocyte-macrophage colony-stimulating factor given sequentially with continuous infusion vinblastine in metastatic breast cancer patients.
American journal of clinical oncology 1993;16(2):132-6.
1993: Deisseroth A B; Hanania E G; Fu S; Claxton D; Andreeff M; Champlin R; Kavanagh J; Hortobagyi G; Holmes F; Reading C
Genetic therapy of human neoplastic disease.
Journal of hematotherapy 1993;2(3):373-5.
1992: Hortobagyi G N
Activity of ifosfamide in breast cancer.
Seminars in oncology 1992;19(6 Suppl 12):36-41.
1992: Voravud N; Theriault R; Hortobagyi G
Vertebral osteomyelitis mimicking bone metastasis in breast cancer patients.
American journal of clinical oncology 1992;15(5):428-32.
1992: Buzdar A U; Hortobagyi G N; Kau S W; Smith T L; Fraschini G; Holmes F A; Gutterman J U; Hug V M; Singletary S E; Ames F C
Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(10):1540-6.
1992: Booser D J; Hortobagyi G N
Treatment of locally advanced breast cancer.
Seminars in oncology 1992;19(3):278-85.
1992: Jaiyesimi I A; Buzdar A U; Hortobagyi G
Inflammatory breast cancer: a review.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(6):1014-24.
1992: Singletary S E; McNeese M D; Hortobagyi G N
Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma.
Cancer 1992;69(11):2849-52.
1992: Walters R S; Theriault R L; Holmes F A; Hortobagyi G N; Esparza L
Phase II trial of fazarabine (ARA-AC, arabinosyl-5-azacytosine) in metastatic breast cancer.
Investigational new drugs 1992;10(1):43-4.
1992: Walters R S; Frye D; Buzdar A U; Holmes F A; Hortobagyi G N
A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma.
Cancer 1992;69(2):476-81.
1992: Buzdar A U; Kau S W; Hortobagyi G N; Ames F C; Holmes F A; Fraschini G; Hug V; Theriault R L; McNeese M D; Singletary S E
Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy.
Cancer 1992;69(2):448-52.
1992: Simmons J R; Buzdar A U; Ota D M; Marts K; Hortobagyi G N
Complications associated with indwelling catheters.
Medical and pediatric oncology 1992;20(1):22-5.
1992: Dhingra K; Sahin A; Supak J; Kim S Y; Hortobagyi G; Hittelman W N
Chromosome in situ hybridization on formalin-fixed mammary tissue using non-isotopic, non-fluorescent probes: technical considerations and biological implications.
Breast cancer research and treatment 1992;23(3):201-10.
1992: Hortobagyi G N
Overview of new treatments for breast cancer.
Breast cancer research and treatment 1992;21(1):3-13.
1991: Holmes F A; Walters R S; Theriault R L; Forman A D; Newton L K; Raber M N; Buzdar A U; Frye D K; Hortobagyi G N
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.
Journal of the National Cancer Institute 1991;83(24):1797-805.
1991: Fraschini G; Holmes F A; Esparza L; Theriault R L; Buzdar A U; Hortobagyi G N
Phase I-II study of high-dose etoposide in patients with refractory breast cancer.
Investigational new drugs 1991;9(4):365-7.
1991: Huan S D; Yau J C; Dunphy F R; Wallerstein R O; Dicke K; Spencer V; LeMaistre C F; Deisseroth A B; Hortobagyi G N; Holmes F A
Impact of autologous bone marrow infusion on hematopoietic recovery after high-dose cyclophosphamide, etoposide, and cisplatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(9):1609-17.
1991: Hortobagyi G N
Bone metastases in breast cancer patients.
Seminars in oncology 1991;18(4 Suppl 5):11-5.
1991: Macheledt J E; Buzdar A U; Hortobagyi G N; Frye D K; Gutterman J U; Holmes F A
Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer.
Breast cancer research and treatment 1991;18(3):165-70.
1991: Ziegler L D; Connelly J H; Frye D; Smith T L; Hortobagyi G N
Lack of correlation between histologic findings and response to chemotherapy in metastatic breast cancer.
Cancer 1991;68(3):628-33.
1991: Sahin A A; Ro J; Ro J Y; Blick M B; el-Naggar A K; Ordonez N G; Fritsche H A; Smith T L; Hortobagyi G N; Ayala A G
Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis.
Cancer 1991;68(3):549-57.
1991: Fraschini G; Ciociola A; Esparza L; Templeton D; Holmes F A; Walters R S; Hortobagyi G N
Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(7):1268-74.
1991: Pathak S; Hopwood V L; Hortobagyi G N; Jackson G L; Hughes J I; Melillo D
Chromosome anomalies in human breast cancer: evidence for specific involvement of 1q region in lymphocyte cultures.
Anticancer research 1991;11(3):1055-60.
1991: Hug V; Kau S; Hortobagyi G N; Jones L
Adrenal failure in patients with breast carcinoma after long-term treatment of cyclic alternating oestrogen progesterone.
British journal of cancer 1991;63(3):454-6.
1991: Broadwater J R; Edwards M J; Kuglen C; Hortobagyi G N; Ames F C; Balch C M
Mastectomy following preoperative chemotherapy. Strict operative criteria control operative morbidity.
Annals of surgery 1991;213(2):126-9.
1990: Wallerstein R; Spitzer G; Dunphy F; Huan S; Hortobagyi G; Yau J; Buzdar A; Holmes F; Theriault R; Ewer M
A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(11):1782-8.
1990: Hortobagyi G N
Comprehensive management of locally advanced breast cancer.
Cancer 1990;66(6 Suppl):1387-91.
1990: Ro J; Sahin A; Ro J Y; Fritsche H; Hortobagyi G; Blick M
Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer.
Human pathology 1990;21(8):787-91.
1990: Dunphy F R; Spitzer G; Buzdar A U; Hortobagyi G N; Horwitz L J; Yau J C; Spinolo J A; Jagannath S; Holmes F; Wallerstein R O
Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(7):1207-16.
1990: Holmes F A; Fritsche H A; Loewy J W; Geitner A M; Sutton R C; Buzdar A U; Hortobagyi G N
Measurement of estrogen and progesterone receptors in human breast tumors: enzyme immunoassay versus binding assay.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(6):1025-35.
1990: Katz R L; Patel S; Sneige N; Fritsche H A; Hortobagyi G N; Ames F C; Brooks T; Ordonez N G
Comparison of immunocytochemical and biochemical assays for estrogen receptor in fine needle aspirates and histologic sections from breast carcinomas.
Breast cancer research and treatment 1990;15(3):191-203.
1990: Sutton R; Buzdar A U; Hortobagyi G N
Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients.
Cancer 1990;65(4):847-50.
1990: Buzdar A U; McNeese M D; Hortobagyi G N; Smith T L; Kau S; Fraschini G; Hug V; Ellerbroek N; Holmes F A; Ames F
Is chemotherapy effective in reducing the local failure rate in patients with operable breast cancer?
Cancer 1990;65(3):394-9.
1990: Buzdar A U; Hortobagyi G N; Esparza L T; Holmes F A; Ro J S; Fraschini G; Lichtiger B
Elliptinium acetate in metastatic breast cancer--a phase II study.
Oncology 1990;47(2):101-4.
1990: Hortobagyi G N; Theriault R L; Frye D; Walters R S; Fraschini G; Tashima C K; Ro J S; Salewski E; Buzdar A U
Pirarubicin in combination chemotherapy for metastatic breast cancer.
American journal of clinical oncology 1990;13 Suppl 1():S54-6.
1990: Vanek N; Hortobagyi G N; Buzdar A U
Radiotherapy enhances the toxicity of aminoglutethimide.
Medical and pediatric oncology 1990;18(2):162-4.
1989: Givens S S; Ellerbroek N A; Butler J J; Libshitz H I; Hortobagyi G N; McNeese M D
Angiosarcoma arising in an irradiated breast. A case report and review of the literature.
Cancer 1989;64(11):2214-6.
1989: Ro J S; el-Naggar A; Ro J Y; Blick M; Frye D; Fraschini G; Fritsche H; Hortobagyi G
c-erbB-2 amplification in node-negative human breast cancer.
Cancer research 1989;49(24 Pt 1):6941-4.
1989: Ang P T; Buzdar A U; Smith T L; Kau S; Hortobagyi G N
Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(11):1677-84.
1989: Koh E H; Ro J; Wildrick D M; Hortobagyi G N; Blick M
Analysis of the estrogen receptor gene structure in human breast cancer.
Anticancer research 1989;9(6):1841-5.
1989: Patel H Z; Buzdar A U; Hortobagyi G N
Role of adjuvant chemotherapy in male breast cancer.
Cancer 1989;64(8):1583-5.
1989: Hortobagyi G N; Hug V; Buzdar A U; Kau S W; Holmes F A; Fritsche H A
Sequential cyclic combined hormonal therapy for metastatic breast cancer.
Cancer 1989;64(5):1002-6.
1989: Jabboury K; Holmes F A; Hortobagyi G
5-Fluorouracil rechallenge by protracted infusion in refractory breast cancer.
Cancer 1989;64(4):793-7.
1989: Jabboury K; Frye D; Holmes F A; Fraschini G; Hortobagyi G
Phase II evaluation of gallium nitrate by continuous infusion in breast cancer.
Investigational new drugs 1989;7(2-3):225-9.
1989: Taha M; Ordoñez N G; Kulkarni S; Owen M; Ro J S; Hortobagyi G; Reading C L; Dicke K A; Spitzer G
A monoclonal antibody cocktail for detection of micrometastatic tumor cells in the bone marrow of breast cancer patients.
Bone marrow transplantation 1989;4(3):297-303.
1989: Buzdar A U; Kau S W; Smith T L; Hortobagyi G N
Ten-year results of FAC adjuvant chemotherapy trial in breast cancer.
American journal of clinical oncology 1989;12(2):123-8.
1989: Theriault R L; Hortobagyi G N; Fritsche H A; Frye D; Martinez R; Buzdar A U
The role of serum CEA as a prognostic indicator in stage II and III breast cancer patients treated with adjuvant chemotherapy.
Cancer 1989;63(5):828-35.
1989: Chu P S; Buzdar A U; Hortobagyi G N
Trilostane with hydrocortisone in treatment of metastatic breast cancer.
Breast cancer research and treatment 1989;13(2):117-21.
1989: Ro J; Bresser J; Ro J Y; Brasfield F; Hortobagyi G; Blick M
SIS/PDGF-B expression in benign and malignant human breast lesions.
Oncogene 1989;4(3):351-4.
1989: Hortobagyi G N; Yap H Y; Kau S W; Fraschini G; Ewer M S; Chawla S P; Benjamin R S
A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer.
American journal of clinical oncology 1989;12(1):57-62.
1989: Hortobagyi G N; Frye D; Buzdar A U; Ewer M S; Fraschini G; Hug V; Ames F; Montague E; Carrasco C H; Mackay B
Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma.
Cancer 1989;63(1):37-45.
1989: Sneige N; White V A; Katz R L; Troncoso P; Libshitz H I; Hortobagyi G N
Ductal carcinoma-in-situ of the breast: fine-needle aspiration cytology of 12 cases.
Diagnostic cytopathology 1989;5(4):371-7.
1988: Hortobagyi G N; Ames F C; Buzdar A U; Kau S W; McNeese M D; Paulus D; Hug V; Holmes F A; Romsdahl M M; Fraschini G
Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy.
Cancer 1988;62(12):2507-16.
1988: Theriault R L; Hortobagyi G N; Kau S W; Holmes F A; Hug V; Fraschini G; Jabboury K; Buzdar A U
Sequential multiagent chemotherapy incorporating cisplatin, doxorubicin, and cyclophosphamide in the treatment of metastatic breast cancer.
Cancer 1988;62(10):2105-10.
1988: Buzdar A U; Hortobagyi G N; Smith T L; Kau S; Marcus C; Holmes F A; Hug V; Fraschini G; Ames F C; Martin R G
Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs.
Cancer 1988;62(10):2098-104.
1988: Hortobagyi G N
The role of high-dose chemotherapy with autologous bone marrow transplantation in the treatment of breast cancer.
Bone marrow transplantation 1988;3(6):525-30.
1988: Hortobagyi G N; Buzdar A U
Management of locally advanced breast cancer.
American journal of clinical oncology 1988;11(5):597-601.
1988: Fraschini G; Holmes F A; Buzdar A U; Hug V; Hortobagyi G N
Cisplatin in combination with continuous infusion vinblastine for refractory breast cancer.
American journal of clinical oncology 1988;11(4):448-50.
1988: Berté E; Buzdar A U; Smith T L; Hortobagyi G N
Bilateral primary breast cancer in patients treated with adjuvant therapy.
American journal of clinical oncology 1988;11(2):114-8.
1988: Fraschini G; Charnsangavej C; Carrasco C H; Buzdar A U; Jabboury K W; Hortobagyi G N
Percutaneous hepatic arterial infusion of cisplatin-vinblastine for refractory breast carcinoma metastatic to the liver.
American journal of clinical oncology 1988;11(1):34-8.
1988: Ro J; North S M; Gallick G E; Hortobagyi G N; Gutterman J U; Blick M
Amplified and overexpressed epidermal growth factor receptor gene in uncultured primary human breast carcinoma.
Cancer research 1988;48(1):161-4.
1988: Buzdar A U; Marcus C; Holmes F; Hug V; Hortobagyi G
Phase II evaluation of Ly156758 in metastatic breast cancer.
Oncology 1988;45(5):344-5.
1987: Hortobagyi G N; Frye D; Holmes F A; Hug V; Fraschini G; Buzdar A U
Phase II study of iproplatin in metastatic breast carcinoma.
Cancer treatment reports 1987;71(12):1193-6.
1987: Hortobagyi G N; Buzdar A U; Frye D; Hug V; Fraschini G; Ames F C; Montague E; Gutterman J U; Martin R G
Combined antiestrogen and cytotoxic therapy with pseudomonas vaccine immunotherapy for metastatic breast cancer. A prospective, randomized trial.
Cancer 1987;60(11):2596-604.
1987: Fraschini G; Fleishman G; Charnsangavej C; Carrasco C H; Hortobagyi G N
Continuous 5-day infusion of vinblastine for percutaneous hepatic arterial chemotherapy for metastatic breast cancer.
Cancer treatment reports 1987;71(11):1001-5.
1987: Fraschini G; Fleishman G; Yap H Y; Carrasco C H; Charnsangavej C; Patt Y Z; Hortobagyi G N
Percutaneous hepatic arterial infusion of cisplatin for metastatic breast cancer.
Cancer treatment reports 1987;71(3):313-5.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Gabriel Hortobagyi

Research Profile (preview)

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Gabriel Hortobagyi (preview)

All Publications